[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15316
1. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M: Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol; 2008 Feb;83(2):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
  • Mantle cell lymphoma (MCL), an aggressive non-Hodgkin's lymphoma characterized by t(11; 14)(q13;.
  • q32) chromosomal translocation and overexpression of cyclin D1, has the worst prognosis among all lymphomas.
  • It is more effective when used in combination with chemotherapy such as R-CHOP, R-hyperCVAD/MTX-Ara-C, or R-FCM as front-line or salvage therapy for mantle cell lymphoma.
  • Although most results have suggested that combining autologous stem cell transplantation with Rituximab may lead to durable remission, the sample size was not sufficient to declare survival benefit.
  • Anti-CD20 radioimmunoconjugates (RICs) (90)Yttrium-ibritumomab tiuxetan and (131)Iodine-tositumomab have been used in mantle cell lymphoma even when patients are relatively resistant to Rituximab-based therapy.
  • Allogeneic stem cell transplantation is a treatment modality in advanced or relapsed MCL, particularly using reduced-intensity conditioning.
  • Dendritic cells (DCs) fused with MCL cells for immunostimulation have preliminarily shown anti-lymphoma effects as well.
  • Idiotype vaccination in MCL patients following Rituximab-containing chemotherapy induced tumor-specific T-cell immunity in the absence of B cells.
  • [MeSH-major] Antigens, CD20 / immunology. Immunotherapy / methods. Lymphoma, Mantle-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / immunology. Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Dendritic Cells / immunology. Graft vs Tumor Effect. Humans. Rituximab


2. Ran LW, Tan SS, Wang WJ, Qiu S, Lei XB, Zeng WH: [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug;25(8):972-4, 978
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance].
  • OBJECTIVE: To investigate the effects of all-trans retinoic acid (ATRA), acitretin and tazarotene on apoptosis and Bax/Bcl-2 protein expressions of human melanoma A375 cells.
  • METHODS: The effects of retinoids on apoptosis and Bax/Bcl-2 protein expressions of A375 cells in vitro were examined.
  • SABC immunocytochemistry was employed for detection of Bax/Bcl-2 protein expressions.
  • RESULTS: At the concentration of 1 x 10(-5) mol/L, ATRA, acitretin and tazarotene all induced apoptosis of A375 cells with apoptosis ratio of 5.03% (P<0.05), 13.42% (P<0.05) and 2.88% (P>0.05), respectively, and acitretin induced more significant apoptosis than the other two agents (P<0.05).
  • In addition, all the three agents significantly increased the number of cells positive for Bax expression and decreased the number of cells expressing Bcl-2 (P<0.05), among which acitretin had the strongest effects.
  • CONCLUSIONS: ATRA, acitretin and tazarotene mediate apoptosis of A375 cells possibly through, at least partially, the mitochondrial pathway.
  • [MeSH-minor] Humans. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tumor Cells, Cultured. bcl-2-Associated X Protein / biosynthesis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ACITRETIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109552.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nicotinic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 5688UTC01R / Tretinoin; 81BDR9Y8PS / tazarotene; LCH760E9T7 / Acitretin
  •  go-up   go-down


3. Ansell SM, Armitage J: Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc; 2005 Aug;80(8):1087-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma: diagnosis and treatment.
  • Non-Hodgkin lymphomas are a heterogeneous group of malignancies of the lymphoid system.
  • Based on the World Health Organization classification of hematological and lymphoid tumors, these diseases have been classified as B-cell and T-cell neoplasms.
  • B-cell lymphomas account for approximately 90% of all lymphomas, and the 2 most common histological disease entities are follicular lymphoma and diffuse large B-cell lymphoma.
  • Approximately 55,000 to 60,000 new cases of non-Hodgkin lymphoma are diagnosed annually in the United States, a number that has nearly doubled during the past 3 decades.
  • The Ann Arbor Staging Classification is used routinely to classify the extent of disease, and the International Prognostic Index has been used to define prognostic subgroups.
  • Treatment of these diseases is based on the histology and extent of disease.
  • Patients with follicular lymphomas with early-stage disease generally are treated with radiation therapy, whereas those with stage III and IV disease requiring treatment usually are treated with chemotherapy, Immunotherapy, or radioimmunotherapy.
  • For patients with diffuse large B-cell lymphoma, treatment of limited-stage disease generally includes doxorubicin-based chemotherapy combined with rituximab followed by involved field radiation therapy.
  • Those with extensive disease are treated with rituximab combined with chemotherapy alone.
  • Disease relapse is a problem, and high-dose therapy with stem cell support is the treatment of choice for chemosensitive relapsed aggressive lymphomas.
  • Patients with chemoresistant disease or whose disease relapses subsequently should be treated with novel experimental therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. L-Lactate Dehydrogenase / blood. Middle Aged. Phenotype. Prognosis. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092591.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 74
  •  go-up   go-down


Advertisement
4. Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L: Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol; 2010 Jun;28(2):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
  • Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene.
  • The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL).
  • While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic and cytogenetics intermediate between DLBCL and BL, and cannot be classified with certainty in these categories.
  • This review summarizes the current practical approach, including the use of a large panel of antibodies, and cytogenetic and molecular diagnostic techniques, to distinguish between BL, DLBCL and the provisional category of 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma', now listed in the updated WHO classification.
  • [MeSH-major] B-Lymphocytes / pathology. Burkitt Lymphoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Biopsy. Child. Diagnosis, Differential. Disease Management. Gene Expression Profiling. Genes, Immunoglobulin. Genes, bcl-2. Genes, myc. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Translocation, Genetic

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19844983.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


5. Aleman BM, Haas RL, van der Maazen RW: Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract.
  • In patients with gastrointestinal lymphoma the most frequently involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum.
  • The most common histological subtypes are extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL).
  • The role of radiotherapy is most definite in early stage gastric lymphoma.
  • The therapeutic approach for patients with gastric Non Hodgkin lymphoma (NHL) has changed significantly over the last decades.
  • The primary treatment of limited gastric MALT lymphoma consists of Helicobacter pylori eradication.
  • [MeSH-major] Intestinal Neoplasms / radiotherapy. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Radiotherapy, Intensity-Modulated. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Chemotherapy, Adjuvant. Dose Fractionation. Helicobacter pylori / pathogenicity. Humans. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206106.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 46
  •  go-up   go-down


6. Coutinho AB, Muccioli C, Martins MC, Belfort Jr R, Sant'Anna AE, Burnier Jr MN: Extranodal B-cell lymphoma of the uvea: a case report. Can J Ophthalmol; 2005 Oct;40(5):623-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal B-cell lymphoma of the uvea: a case report.
  • CASE REPORT: Ocular involvement by non-Hodgkin's lymphoma is a rare condition that can result from a primary intraocular lymphoma of the retina or an intraocular manifestation of systemic lymphoma.
  • Uveal involvement is seldom the initial manifestation of extranodal lymphoma.
  • After ultrasound evaluation, the eye was enucleated and histopathologic examination revealed a malignant B-cell lymphoma of the uveal tract.
  • The patient has been followed for 8 years after surgery, but she has had no further systemic manifestations of lymphoma and has not required subsequent treatment.
  • COMMENTS: Primary extranodal lymphoma can be easily mistaken for recurrent uveitis or primary intraocular lymphoma of the retina and central nervous system; it is a differential diagnosis to be considered in cases of recurrent uveitis-like symptoms evolving to blind painful eye.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391629.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Smedby KE, Hjalgrim H, Melbye M, Torrång A, Rostgaard K, Munksgaard L, Adami J, Hansen M, Porwit-MacDonald A, Jensen BA, Roos G, Pedersen BB, Sundström C, Glimelius B, Adami HO: Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst; 2005 Feb 2;97(3):199-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation exposure and risk of malignant lymphomas.
  • BACKGROUND: The incidence of malignant lymphomas has been increasing rapidly, but the causes of these malignancies remain poorly understood.
  • One hypothesis holds that exposure to ultraviolet (UV) radiation increases lymphoma risk.
  • METHODS: A total of 3740 patients diagnosed between October 1, 1999, and August 30, 2002, with incident malignant lymphomas, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Hodgkin lymphoma, and 3187 population controls provided detailed information on history of UV exposure and skin cancer and information on other possible risk factors for lymphomas.
  • RESULTS: Multivariable-adjusted analyses revealed consistent, statistically significant negative associations between various measures of UV light exposure and risk of non-Hodgkin lymphoma.
  • A high frequency of sun bathing and sunburns at age 20 years and 5-10 years before the interview and sun vacations abroad were associated with 30%-40% reduced risks of non-Hodgkin lymphoma (e.g., for sunbathing four times a week or more at age 20 versus never sunbathing, OR = 0.7, 95% CI = 0.6 to 0.9; for two or more sunburns a year at age 20 versus no sunburns, OR = 0.6, 95% CI = 0.5 to 0.8).
  • Similar, albeit weaker, associations were observed for Hodgkin lymphoma.
  • There were no clear differences among non-Hodgkin lymphoma subtypes, although associations were stronger for B-cell than for T-cell lymphomas.
  • A history of skin cancer was associated with a doubling in risks of both non-Hodgkin and Hodgkin lymphoma.
  • CONCLUSIONS: A history of high UV exposure was associated with reduced risk of non-Hodgkin lymphoma.
  • The positive association between skin cancer and malignant lymphomas is, therefore, unlikely to be mediated by UV exposure.
  • [MeSH-major] Lymphoma / epidemiology. Ultraviolet Rays
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Confidence Intervals. Confounding Factors (Epidemiology). Denmark / epidemiology. Female. Hodgkin Disease / epidemiology. Humans. Incidence. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Logistic Models. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Risk Assessment. Risk Factors. Surveys and Questionnaires. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Feb 2;97(3):161-3 [15687354.001]
  • [CommentIn] J Natl Cancer Inst. 2005 Aug 3;97(15):1158; author reply 1159-62 [16077076.001]
  • (PMID = 15687363.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01 CA69269-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


8. Park S, Kim K, Kim WS, Yoo KH, Koo HH, Ko YH: Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. Virchows Arch; 2008 Aug;453(2):155-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients.
  • Fulminant Epstein-Barr virus (EBV+) T-cell lymphoma in immunocompetent elderly patients is rare and its character has not been well defined.
  • This study analyzed the clinicopathological features of five elderly patients (group A: 50-84 years) and compared them with those of eight children and young adult patients with systemic T-cell lymphomas (group B: 10-34 years).
  • All patients died within 1 to 14 months of diagnosis.
  • These findings suggest that EBV+ T-cell lymphoma in elderly patients is a unique disease with an underlying derangement of T-cell immunity and failure to eradicate infected virus.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jul 15;96(2):443-51 [10887104.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):124-31 [16937360.001]
  • [Cites] Blood. 2001 Jul 15;98(2):280-6 [11435294.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1882-8 [11535525.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1165-74 [15067338.001]
  • [Cites] J Infect Dis. 2004 Sep 1;190(5):985-8 [15295706.001]
  • [Cites] Pediatrics. 1985 Jun;75(6):1003-10 [2987784.001]
  • [Cites] Ann Intern Med. 1986 May;104(5):636-43 [3008616.001]
  • [Cites] N Engl J Med. 1988 Mar 24;318(12):733-41 [2831453.001]
  • [Cites] Nature. 1988 Jun 2;333(6172):455-7 [2836734.001]
  • [Cites] J Clin Invest. 1989 Jul;84(1):51-5 [2544630.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2557-62 [2174302.001]
  • [Cites] Clin Microbiol Rev. 1991 Jan;4(1):129-35 [1848476.001]
  • [Cites] Am J Clin Pathol. 1992 Feb;97(2):189-94 [1372145.001]
  • [Cites] N Engl J Med. 1992 Jul 2;327(1):58 [1317943.001]
  • [Cites] Leukemia. 1992 Sep;6(9):952-6 [1325583.001]
  • [Cites] Am J Clin Pathol. 1992 Sep;98(3):324-33 [1326893.001]
  • [Cites] Ann Intern Med. 1993 Jan 1;118(1):45-58 [8380053.001]
  • [Cites] J Clin Invest. 1993 Sep;92(3):1444-50 [8397226.001]
  • [Cites] Hum Pathol. 1993 Oct;24(10):1135-9 [8406423.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3259-64 [8241498.001]
  • [Cites] Eur J Pediatr. 1994 Oct;153(10):734-8 [7813531.001]
  • [Cites] Leuk Lymphoma. 1995 Nov;19(5-6):401-6 [8590839.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1446-57 [8608235.001]
  • [Cites] Nat Med. 1996 Aug;2(8):906-11 [8705861.001]
  • [Cites] Am J Hematol. 1997 Apr;54(4):276-81 [9092681.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2085-91 [9490694.001]
  • [Cites] Am J Kidney Dis. 1998 Nov;32(5):785-93 [9820448.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):42-6 [10029811.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):589-97 [17065428.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2106-16 [11066052.001]
  • (PMID = 18636273.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2516298
  •  go-up   go-down


9. Li S, Phong M, Lahn M, Brail L, Sutton S, Lin BK, Thornton D, Liao B: Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biol Direct; 2007;2:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas.
  • BACKGROUND: Both mechanistic features and recent correlative findings suggest a potential role for protein kinase C-beta (PKC-beta) in tumor pathogenesis, particularly in B-cell malignancies.
  • RESULTS: Our analysis showed that the level of PKC-beta expression was highest in chronic lymphocytic leukemia and follicular lymphoma.
  • Within diffuse large-B cell lymphoma (DLBCL), PKC-beta expression was significantly higher in activated B-cell- like subtype than germinal center B-cell- like subtype (P < 0.0001).
  • Results of global gene expression analyses of DLBCL samples corroborate previous observations that anti-apoptosis, cell proliferation, and B-cell proliferation signaling pathways are functionally related to PKC-beta.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7462-9 [16103100.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1377-84 [15920548.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1996 Aug 9;273(5276):788-91 [8670417.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2018-26 [8903320.001]
  • [Cites] Gen Pharmacol. 1998 Nov;31(5):721-8 [9809468.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2655-62 [10072508.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4413-8 [10485491.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • [Cites] Glycoconj J. 2000 May;17(5):315-22 [11261840.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Nat Immunol. 2002 Aug;3(8):780-6 [12118249.001]
  • [Cites] Science. 1992 Oct 23;258(5082):607-14 [1411571.001]
  • [Cites] Blood. 2004 Jul 1;104(1):224-6 [15031203.001]
  • [Cites] J Mol Cell Cardiol. 2005 Oct;39(4):627-36 [16125722.001]
  • (PMID = 17313671.001).
  • [ISSN] 1745-6150
  • [Journal-full-title] Biology direct
  • [ISO-abbreviation] Biol. Direct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1805741
  •  go-up   go-down


10. Mendelson RM, Fermoyle S: Primary gastrointestinal lymphomas: a radiological-pathological review. Part 1: Stomach, oesophagus and colon. Australas Radiol; 2005 Oct;49(5):353-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphomas: a radiological-pathological review. Part 1: Stomach, oesophagus and colon.
  • Primary gastrointestinal lymphomas are most common in the stomach, followed by small intestine and then colon.
  • The most frequently used pathology classification of lymphomas is the Revised European and American Lymphoma /World Health Organization classification.
  • In the stomach, the majority of primary lymphomas are of B-cell origin of mucosa-associated lymphoid tissue (MALT) type.
  • Low-grade MALT lymphomas are associated with Helicobacter pylori infection and often respond to eradication of this organism.
  • High-grade (large B-cell) tumour patterns include infiltrative, polypoid, nodular, ulcerated or a combination.
  • Endoscopy, endoscopic ultrasound and CT are important in diagnosis and staging, although appearances on barium studies should be recognized.
  • Primary colonic lymphomas are rare.
  • Most are of B-cell origin.
  • Even when circumferential, lymphoma rarely causes obstruction.
  • Small bowel lymphomas will be discussed in the forthcoming part 2 of this review.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Esophageal Neoplasms / diagnosis. Lymphoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Barium Sulfate. Contrast Media. Endosonography. Humans. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174173.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  • [Number-of-references] 34
  •  go-up   go-down


11. Yamada SM, Ikawa N, Toyonaga S, Nakabayashi H, Chang Park K, Shimizu K: Primary malignant B-cell-type dural lymphoma: Case report. Surg Neurol; 2006 Nov;66(5):539-43; discussion 543
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant B-cell-type dural lymphoma: Case report.
  • BACKGROUND: The primary malignant dural lymphoma of B-cell type is rare.
  • Our review of the literature (24 cases) indicated that patients with this tumor had female predominance, immunocompetency, and longer survival compared with those with primary malignant intracerebral lymphomas.
  • Based on its clinicopathological features, this dural lymphoma may be classified differently from other types of malignant lymphomas in the central nervous system.
  • CASE DESCRIPTION: The authors report an example of a patient who had a favorable course of malignant dural lymphoma.
  • A 59-year-old woman presented with primary malignant dural lymphoma in the frontal area.
  • Histological diagnosis was a diffuse large B-cell-type lymphoma of intermediate malignancy, but MIB-1 index was extremely high.
  • A combination of subtotal resection and chemotherapy for a primary malignant dural lymphoma is an effective means to attempt cure of this tumor.
  • We believe that chemotherapy is the treatment of choice after subtotal resection of malignant dural lymphomas, as experienced in our case.
  • [MeSH-major] Dura Mater / pathology. Lymphoma, B-Cell / diagnosis. Meningeal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084207.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  • [Number-of-references] 23
  •  go-up   go-down


12. Chen D, Law ME, Theis JD, Gamez JD, Caron LB, Vrana JA, Dogan A: Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. Am J Surg Pathol; 2009 May;33(5):720-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.
  • Cyclin-dependent protein kinase 6 (CDK6), in cooperation with cyclin Ds, drives cell cycle progression from G1 to S phase through phosphorylation and subsequent inactivation of retinoblastoma 1 protein.
  • Alteration of this pathway results in both nonhematologic and hematologic malignancies, which include a small subset of B-cell lymphoproliferative disorders (BLPDs).
  • We identified 5 cases of BLPD that carried CDK6 chromosomal translocations and characterized their clinical, pathologic, immunophenotypic, and genetic features.
  • Common clinical characteristics included marked neoplastic lymphocytosis, systemic lymphadenopathy, splenomegaly, and bone marrow involvement.
  • Three patients were diagnosed with low-grade B-cell lymphoma and had an indolent clinical course, and 2 patients (one who transformed to large B-cell lymphoma, and the other who was initially diagnosed with a high-grade B-cell lymphoma) had an aggressive clinical course.
  • Immunophenotypically, the neoplastic B cells expressed CD5, CDK6, and cytoplasmic retinoblastoma 1 protein in all cases, expressed phospho-RB, p27kip1, and cyclin D2 in most cases, and uniformly lacked expression of all other cyclins.
  • These distinct clinicopathologic and cytogenetic features distinguish the CDK6 translocation-associated BLPDs (CDK6-BLPDs) from other mature B-cell lymphomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1994 Dec 15;8(24):2939-52 [8001816.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Blood. 1995 May 15;85(10):2870-6 [7742549.001]
  • [Cites] Sangre (Barc). 1995 Oct;40(5):425-9 [8553179.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):627-40 [8619427.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):181-3 [8907288.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Nov;92(1):24-7 [8956866.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1250-4 [9102208.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3054-61 [9120257.001]
  • [Cites] Leukemia. 1997 May;11(5):747-58 [9180302.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1214-9 [9264372.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):1015-20 [9346181.001]
  • [Cites] South Med J. 1998 Jun;91(6):584-7 [9634125.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):175-82 [9665478.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):543-50 [10225442.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):319-29 [10478136.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):122-8 [15642391.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):981-2 [15978952.001]
  • [Cites] Hum Pathol. 2005 Nov;36(11):1232-7 [16260278.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4315-21 [16123218.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1109-10 [16861358.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1744-50 [16690963.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1790-9 [16888615.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Curr Treat Options Oncol. 2007 Apr;8(2):97-108 [17634839.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1745-6 [18223179.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2253-60 [18042795.001]
  • [Cites] Leukemia. 2008 Feb;22(2):387-92 [17989712.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5683-90 [18391076.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] J Virol. 1999 Dec;73(12):9917-27 [10559304.001]
  • [Cites] Oncogene. 1999 Nov 4;18(46):6271-7 [10597225.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1843-50 [11337382.001]
  • [Cites] Pathol Int. 2001 Oct;51(10):747-61 [11881727.001]
  • [Cites] Haematologica. 2002 Apr;87(4):357-62 [11940479.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):916-22 [12472568.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):759-64 [12614206.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3181-7 [12515730.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1549-50 [12900351.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1030-4 [14608537.001]
  • [Cites] Leukemia. 2004 May;18(5):953-61 [15029207.001]
  • [Cites] Blood. 1990 Oct 1;76(7):1387-91 [2207314.001]
  • [Cites] J Pathol. 1991 Jan;163(1):13-8 [2002419.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):233-41 [1712662.001]
  • [Cites] Leukemia. 1991 Sep;5(9):799-806 [1682536.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9638-42 [1682919.001]
  • [Cites] Leukemia. 1993 Feb;7(2):241-5 [8426477.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2077-86 [8114739.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):487-91 [8136270.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1633-40 [8183557.001]
  • [Cites] J Cell Sci Suppl. 1994;18:89-96 [7883799.001]
  • (PMID = 19145199.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097274-069001; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / P50 CA097274-069001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / CCND2 protein, human; 0 / CDKN1B protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Immunoglobulin kappa-Chains; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  • [Other-IDs] NLM/ NIHMS87263; NLM/ PMC2674112
  •  go-up   go-down


13. Valera A, Balagué O, Colomo L, Martínez A, Delabie J, Taddesse-Heath L, Jaffe ES, Campo E: IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol; 2010 Nov;34(11):1686-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.
  • Plasmablastic lymphoma (PBL) is an aggressive lymphoma characterized by a terminally differentiated B-cell phenotype that usually occurs in the immunocompromised or elderly patients.
  • Although the clinical and pathologic characteristics of these tumors have been defined, the genetic alterations involved in their pathogenesis are not well known.
  • In this study, we have investigated the chromosomal alterations of MYC, BCL2, BCL6, MALT1, PAX5, and IGH loci using fluorescence in situ hybridization in 42 PBL and 3 extracavitary primary effusion lymphomas.
  • No rearrangements of any of these loci were seen in the primary effusion lymphomas.
  • The oncogenic activation of MYC in these lymphomas may be an important pathogenetic element associated with EBV infection.
  • [MeSH-major] Cytogenetic Analysis. Gene Rearrangement. Genes, Immunoglobulin. Lymphoma, Large B-Cell, Diffuse / genetics. Plasma Cells / immunology. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Nov 15;98(10):3082-6 [11698294.001]
  • [Cites] Haematologica. 2010 Aug;95(8):1342-9 [20418245.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Science. 1997 Apr 25;276(5312):596-9 [9110979.001]
  • [Cites] Haematologica. 1998 Jan;83(1):8-12 [9542317.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4269-78 [9834233.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1528-37 [9850179.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):875-82 [15539380.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Int J Hematol. 2005 May;81(4):315-8 [15914362.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1225-33 [16829212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1310-22 [17721185.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1080-7 [17654686.001]
  • [Cites] Haematologica. 2008 Apr;93(4):623-6 [18326524.001]
  • [Cites] Haematologica. 2008 May;93(5):641-5 [18450732.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jul;47(7):573-90 [18381641.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Int J Surg Pathol. 2009 Apr;17(2):163-6 [18508845.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):245-55 [19832807.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):327-40 [20118770.001]
  • [Cites] Br J Haematol. 2010 May;149(4):484-97 [20346013.001]
  • [Cites] Mod Pathol. 2010 Jul;23(7):991-9 [20348882.001]
  • [Cites] Hematol J. 2001;2(3):172-9 [11920242.001]
  • (PMID = 20962620.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC000550-27
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS237351; NLM/ PMC2982261
  •  go-up   go-down


14. Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, Vallet S, Ricca I, Dell' Aquila M, Pagliano G, Monitillo L, Pollio B, Santo L, Cristiano C, Rocci A, Francese R, Bodoni CL, Borchiellini A, Schinco P, Boccadoro M, Tarella C: Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. Exp Hematol; 2006 Dec;34(12):1680-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.
  • OBJECTIVE: Nonlymphoma-associated bcl-2/IgH rearrangements (NLABRs) are frequently amplified by PCR in blood of lymphoma-free subjects (LFS), but the temporal kinetics and phenotypic nature of NLABR-positive cells are unknown.
  • Cell selection studies were also performed to define the nature of NLABR-bearing clones.
  • RESULTS: Of 125 donors, 16 (12.8%) were found to be bcl-2/IgH positive and were monitored at least every 6 months for a median time of 22 months (range 6-50).
  • Cell separation studies indicate that NLABRs belong to CD19+, CD5-, CD23-, CD10+/- cells.
  • CONCLUSIONS: Our results indicate that NLABR-positive clones are persistent populations phenotypically related to follicular lymphoma (FL).
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Leukocytes, Mononuclear / metabolism. Lymphoma, Follicular / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Separation. Clone Cells. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157165.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


15. Ferro-Flores G, Torres-García E, García-Pedroza L, Arteaga de Murphy C, Pedraza-López M, Garnica-Garza H: An efficient, reproducible and fast preparation of 188Re-anti-CD20 for the treatment of non-Hodgkin's lymphoma. Nucl Med Commun; 2005 Sep;26(9):793-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An efficient, reproducible and fast preparation of 188Re-anti-CD20 for the treatment of non-Hodgkin's lymphoma.
  • BACKGROUND: Therapies using Y-anti-CD20 or I-anti-CD20 have demonstrated their efficacy in patients with B-cell non-Hodgkin's lymphoma.
  • The binding of Re-anti-CD20 to cells was in the same range as I-anti-CD20 (>80%) and was significantly different to cell binding of Re-anti-CEA (<10%).
  • CONCLUSIONS: Optimal reaction conditions were defined enabling high radiochemical purities of Re-anti-CD20 to be obtained routinely and therefore potentially useful in the treatment of non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096583.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 188Re-anti-CD20 monoclonal antibody; 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Radiopharmaceuticals
  •  go-up   go-down


16. Belousova IE, Kazakov DV, Krivolapov IuA: [Current approaches to the diagnosis and treatment of primary cutaneous lymphomas based on the new WHO-EORTC classification of B-cell cutaneous lymphomas]. Arkh Patol; 2007 Nov-Dec;69(6):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current approaches to the diagnosis and treatment of primary cutaneous lymphomas based on the new WHO-EORTC classification of B-cell cutaneous lymphomas].
  • The review concerns the current approaches to the diagnosis of primary cutaneous lymphomas.
  • B-cell lymphomas are described with the reference to their clinical presentation, histological, and immunohistochemical features and genetic alterations based on the new WHO-EORTC classification of cutaneous lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Skin Neoplasms / diagnosis


17. Sohani AR, Hasserjian RP: Diagnosis of Burkitt Lymphoma and Related High-Grade B-Cell Neoplasms. Surg Pathol Clin; 2010 Dec;3(4):1035-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of Burkitt Lymphoma and Related High-Grade B-Cell Neoplasms.
  • Burkitt lymphoma (BL) is an aggressive B-cell neoplasm with an extremely short doubling time that mainly affects children and young adults.
  • Despite having several characteristic features, none is entirely specific for BL and the differential diagnosis may include diffuse large B-cell lymphoma (DLBCL), B lymphoblastic leukemia/lymphoma, and B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL.
  • We outline a practical approach to establish a diagnosis of BL and distinguish it from other high-grade B-cell malignancies.
  • We pay particular attention to B-cell lymphomas with features intermediate between DLBCL and BL, a new diagnostic category in the 2008 World Health Organization classification system that provides a framework for categorizing challenging cases not meeting diagnostic criteria for either "classic" BL or DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 26839298.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute lymphoblastic lymphoma / Burkitt lymphoma / Diffuse large B-cell lymphoma / Epstein-Barr virus / High-grade B-cell lymphoma unclassifiable / MYC
  •  go-up   go-down


18. Ravat FE, Spittle MF, Russell-Jones R: Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol; 2006 Apr;54(4):668-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous T-cell lymphoma occurring after organ transplantation.
  • Lymphoma occurring after organ transplantation has been well described.
  • The majority of cases are B-cell lymphomas and are usually associated with Epstein-Barr virus.
  • Only a minority of posttransplant lymphomas are of T-cell origin, and primary cutaneous T-cell lymphoma (CTCL) is extremely rare.
  • In this article, we report a case of cutaneous peripheral T-cell lymphoma, pleomorphic CD30+ large-cell type, and review the literature relating to posttransplant primary CTCL.
  • Of the 23 cases of posttransplant primary CTCL, 5 patients had erythrodermic disease, and 8 had primary cutaneous anaplastic large cell lymphoma.
  • In addition, there are two cases of mycosis fungoides, one case of subcutaneous panniculitis-like T-cell lymphoma, one case of CD30+ lymphomatoid papulosis, and 6 cases of peripheral T-cell lymphoma, of which 3 were CD30+ large cell lymphomas.
  • The sex ratio was 18:5 (male/female), and the mean age at diagnosis was 53 years.
  • Mean time from transplantation to diagnosis is 6.4 years and mean survival time from diagnosis is 14.5 months.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Humans. Immunosuppression / adverse effects. Lymphoma, T-Cell, Peripheral / diagnosis. Male. Middle Aged


19. Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G, Intergruppo Italiano Linfomi: NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol; 2006 May;17(5):794-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.
  • OBJECTIVE: To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients.
  • PATIENTS: Between 1997 and 2004, 26 new cases of NK/T-cell lymphoma 'nasal type' were diagnosed in 10 Italian Hematology institutions.
  • In 23 cases presentation at the onset was in the nasal cavity or adjacent structures, in two cases the lymphoma onset with skin lesions was followed successively by rhynopharyngeal dissemination, while the remaining case had bone marrow and lymph node involvement followed by oro-pharyngeal involvement.
  • Regarding the stage of disease: 12 patients were in stage I; six in stage II; eight in stage IV.
  • Diagnosis was based on the finding of a NK/T-cell phenotype at the histological and immunophenotypic examination of oropharyngeal or cutaneous lesions.
  • The median disease-free survival was 14 months and the median overall survival time was 9 months.
  • CONCLUSION: The results of this retrospective survey confirmed that NK/T-cell lymphoma 'nasal type' is a very rare lymphoma in the Italian population, and it is characterized by a very bad prognosis.
  • Due to the rarity of this disease, a standardized therapeutic approach is lacking.
  • More data are needed to know the epidemiology of this kind of lymphoma in Europe.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497823.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol; 2009 Oct 20;27(30):5023-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
  • PURPOSE: To determine overall response rate (ORR), time to progression (TTP), and duration of response (DOR) with twice-weekly/weekly bortezomib plus rituximab, and evaluate safety/tolerability, in patients with relapsed or refractory CD20(+) follicular lymphoma (FL) or marginal-zone lymphoma.
  • CONCLUSION: Both bortezomib plus rituximab regimens seem feasible in relapsed or refractory indolent lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770386.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


21. Cobaleda C, Schebesta A, Delogu A, Busslinger M: Pax5: the guardian of B cell identity and function. Nat Immunol; 2007 May;8(5):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax5: the guardian of B cell identity and function.
  • This transcriptional reprogramming restricts the broad signaling capacity of uncommitted progenitors to the B cell pathway, regulates cell adhesion and migration, induces V(H)-DJ(H) recombination, facilitates (pre-)B cell receptor signaling and promotes development to the mature B cell stage.
  • Conditional Pax5 inactivation in early and late B lymphocytes revealed an essential role for Pax5 in controlling the identity and function of B cells throughout B lymphopoiesis.
  • PAX5 has also been implicated in human B cell malignancies, as it is deregulated by chromosomal translocations in a subset of acute lymphoblastic leukemias and non-Hodgkin lymphomas.
  • [MeSH-major] B-Lymphocytes / metabolism. Cell Differentiation / genetics. Gene Expression Regulation, Developmental / physiology. PAX5 Transcription Factor / physiology
  • [MeSH-minor] Animals. Cell Lineage. Cell Transformation, Neoplastic / genetics. Humans

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440452.001).
  • [ISSN] 1529-2908
  • [Journal-full-title] Nature immunology
  • [ISO-abbreviation] Nat. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9900989; United States / NHGRI NIH HHS / HG / R01 HG005085
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX5 Transcription Factor; 0 / PAX5 protein, human; 0 / Pax5 protein, mouse
  • [Number-of-references] 77
  •  go-up   go-down


22. Costa ES, Pedreira CE, Barrena S, Lecrevisse Q, Flores J, Quijano S, Almeida J, del Carmen García-Macias M, Bottcher S, Van Dongen JJ, Orfao A: Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia; 2010 Nov;24(11):1927-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping.
  • Immunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is becoming increasingly complex due to usage of progressively larger panels of reagents and a high number of World Health Organization (WHO) entities.
  • Typically, data analysis is performed separately for each stained aliquot of a sample; subsequently, an expert interprets the overall immunophenotypic profile (IP) of neoplastic B-cells and assigns it to specific diagnostic categories.
  • Three reference groups of immunophenotypic data files-B-cell chronic lymphocytic leukemias (B-CLL; n = 10), mantle cell (MCL; n = 10) and follicular lymphomas (FL; n = 10)--were built.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / immunology. Automation. Female. Flow Cytometry / methods. Humans. Immunoglobulin A / immunology. Immunophenotyping / methods. Lymphoma / immunology. Lymphoma / pathology. Lymphoma, Follicular / immunology. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / immunology. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):367-84 [17707827.001]
  • [Cites] Clin Lab Med. 2007 Sep;27(3):469-85, v [17658403.001]
  • [Cites] Cytometry B Clin Cytom. 2007;72 Suppl 1:S14-22 [17803189.001]
  • [Cites] Cytometry B Clin Cytom. 2007;72 Suppl 1:S23-33 [17803190.001]
  • [Cites] Haematologica. 2008 Feb;93(2):215-23 [18223290.001]
  • [Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]
  • [Cites] Haematologica. 2008 Apr;93(4):551-9 [18379010.001]
  • [Cites] Am J Hematol. 2008 May;83(5):349-54 [18186522.001]
  • [Cites] Blood. 2008 May 15;111(10):5130-41 [18337555.001]
  • [Cites] Mayo Clin Proc. 2008 Jul;83(7):776-85 [18613994.001]
  • [Cites] Cytometry A. 2008 Sep;73(9):834-46 [18629843.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 [18548617.001]
  • [Cites] Cytometry A. 2008 Dec;73A(12):1141-50 [18836994.001]
  • [Cites] Leukemia. 2009 Mar;23(3):528-34 [19020543.001]
  • [Cites] Blood. 2009 Jul 2;114(1):33-7 [19420353.001]
  • [Cites] Hematol Oncol. 2009 Sep;27(3):140-7 [19247978.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2007-17 [19641522.001]
  • [Cites] Haematologica. 2010 Apr;95(4):604-12 [20015887.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):205-12 [10068208.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cytometry. 2001 Feb 15;46(1):23-7 [11241503.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):180-3 [11896067.001]
  • [Cites] Hematol J. 2001;2(5):300-6 [11920265.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1460-9 [12145686.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):191-5 [12672094.001]
  • [Cites] Cytometry A. 2004 Mar;58(1):57-61 [14994222.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Sep;72(5):380-6 [17226862.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):153-60 [10440853.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Jan;70(1):39-44 [16353215.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1850-8 [17149963.001]
  • [Cites] Leukemia. 2007 May;21(5):956-64 [17361231.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1204-11 [17410192.001]
  • [ErratumIn] Leukemia. 2011 Feb;25(2):385
  • (PMID = 20844562.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin A
  • [Other-IDs] NLM/ PMC3035971
  •  go-up   go-down


23. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia; 2007 Feb;21(2):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin's lymphoma, with a mean survival of only 3-5 years and suboptimal therapeutic options.
  • As improved therapy for MCL is required and the mTOR pathway may be involved in its pathophysiology, the antiproliferative effects of RAD001 (everolimus), an mTOR inhibitor, against three MCL cell lines were investigated.
  • As a single agent, RAD001 inhibited proliferation in MCL cell lines (Jeko1, SP49 and NCEB1) approximately 40-65% compared to diluent control cells.
  • This was associated with G(1) cell-cycle arrest and reduced phosphorylation of the mTOR downstream target, 4E-BP1.
  • These data indicate that single agent RAD001 is effective in inhibiting growth of MCL cells in vitro and combination studies with secondary agents further demonstrate synergistic cytotoxicity.
  • Thus, these findings support future clinical studies of RAD001 in the treatment of MCL.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Lymphoma, Mantle-Cell / pathology. Sirolimus / analogs & derivatives
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cell Division / drug effects. Cell Line, Tumor. Dimethyl Sulfoxide / pharmacology. Everolimus. Humans


24. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • BACKGROUND: The burden of lymphomas on the health care system in Nigeria is enormous.
  • Correct diagnosis and identification of aetiological factor are important steps in reducing this burden.
  • The clinical characteristics of each patient were documented.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • All were cases of classical HL with 60% being of the mixed cellularity (MC) subtype.
  • 60% of the tumour was EBV positive, all of the MC subtype.
  • CONCLUSION: Mixed cellularity is the most common subtype and is the only subtype associated with EBV positivity in this study.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


25. Cypel M, Belfort R Jr, Moraes N, Muccioli C: [Primary intraocular B-cell lymphoma: case report]. Arq Bras Oftalmol; 2007 Jul-Aug;70(4):709-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular B-cell lymphoma: case report].
  • [Transliterated title] Linfoma intra-ocular primário de células tipo B: relato de caso.
  • Ocular non-Hodgkin's lymphoma is a rare condition that can involve the retina, the vitreous and the optic nerve.
  • It can occur alone or can be associated with lymphoma of the central nervous system and a frequent manifestation is a posterior uveitis of difficult treatment.
  • This kind of ocular tumor is difficult and a challenge to diagnosis.
  • We describe a case of non-Hodgkin's intraocular B-cell lymphoma in a 47-year-old woman who had a posterior uveitis as the first manifestation.
  • We emphasize the importance of a careful investigation and of the general clinical examination since this is the most common type in the eye.
  • We expect to call the attention to this disease that many times appears in an unspecific form with unspecific symptoms.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Female. Humans. Lymphoma, Non-Hodgkin / diagnosis. Middle Aged. Uveitis / diagnosis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906772.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


26. Smedby KE, Hjalgrim H, Chang ET, Rostgaard K, Glimelius B, Adami HO, Melbye M: Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Res; 2007 Nov 15;67(22):11074-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood social environment and risk of non-Hodgkin lymphoma in adults.
  • Better hygiene and sanitation and decreasing family size parallel the increasing incidence of non-Hodgkin lymphoma (NHL) in many populations around the world.
  • Results were slightly stronger for diffuse large B-cell and T-cell lymphomas than for other major NHL subtypes.
  • [MeSH-major] Environment. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology


27. Jantunen E, Kuittinen T: Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues. Eur J Haematol; 2008 Apr;80(4):287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues.
  • More than 15,000 autologous stem cell transplants (ASCT) were reported to European Blood and Bone Marrow Transplantation registry in 2005, most commonly for multiple myeloma (MM) and lymphomas.
  • In 98% of the cases high-dose therapy was supported by blood stem cells.
  • Thus stem cell mobilization and collection are integral parts of ASCT protocols.
  • We give here a practical approach to blood stem cell mobilization and collection in patients with various lymphoproliferative diseases.
  • While mobilization is usually easy and straightforward in patients with MM, about 10-20% of patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma are hard-to-mobilize.
  • There seems to be even more disease-specific issues in blood stem cell mobilization in patients with chronic lymphocytic leukaemia and in patients with light chain amyloidosis.
  • [MeSH-major] Hematopoietic Stem Cell Mobilization. Lymphoproliferative Disorders / therapy. Patients

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182078.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 74
  •  go-up   go-down


28. Rucci F, Cattaneo L, Marrella V, Sacco MG, Sobacchi C, Lucchini F, Nicola S, Della Bella S, Villa ML, Imberti L, Gentili F, Montagna C, Tiveron C, Tatangelo L, Facchetti F, Vezzoni P, Villa A: Tissue-specific sensitivity to AID expression in transgenic mouse models. Gene; 2006 Aug 1;377:150-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AID is able to mutate both Ig-like reporter constructs and selected non-Ig genes in normal B cells and in other cells when ectopically overexpressed in mammalian cells and transgenic mice.
  • However, in spite of the fact that in these transgenic animals AID activity was driven by an ubiquitous promoter, only T lymphomas and lung adenomas occurred.
  • The lck/AID mice developed thymic lymphomas with variable but high efficiency, while no tumor was detected in HTLV-I/AID mice after two years of monitoring.
  • Four MMTV/AID founder mice died with an atypical clinical picture, although no mammary tumor was found.
  • These findings suggest that additional factors, present in thymocytes but not in other tissues or in lymphoid cells at different stages of differentiation, are needed for AID to fully manifest its tumorigenic potential in mouse.
  • Alternatively, the display of full AID mutagenic and transforming activity could be related to the existence of physiologic DSBs which occur in both thymocytes and switching B cells.
  • [MeSH-minor] Animals. Base Sequence. Cell Differentiation. Cell Transformation, Neoplastic. DNA, Complementary / genetics. DNA-Binding Proteins / genetics. Female. Gene Expression. Genes, T-Cell Receptor beta. Genes, myc. Genes, p53. Human T-lymphotropic virus 1 / genetics. Kidney / enzymology. Kidney / pathology. Liver / enzymology. Liver / pathology. Lymph Nodes / enzymology. Lymph Nodes / pathology. Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / genetics. Mammary Glands, Animal / enzymology. Mammary Glands, Animal / pathology. Mammary Tumor Virus, Mouse / genetics. Mice. Mice, Transgenic. Mutation. Promoter Regions, Genetic. T-Lymphocytes / enzymology. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Tissue Distribution

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787714.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Rag2 protein, mouse; EC 2.7.10.2 / Lymphocyte Specific Protein Tyrosine Kinase p56(lck); EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


29. Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H, Lichter P, Bentz M, Döhner H, Möller P, Schwaenen C: Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia; 2007 Dec;21(12):2463-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).
  • Primary mediastinal B-cell lymphoma (PMBL) is an aggressive extranodal B-cell non-Hodgkin's lymphoma with specific clinical, histopathological and genomic features.
  • To characterize further the genotype of PMBL, we analyzed 37 tumor samples and PMBL cell lines Med-B1 and Karpas1106P using array-based comparative genomic hybridization (matrix- or array-CGH) to a 2.8k genomic microarray.
  • [MeSH-major] Chromosome Aberrations. Consensus Sequence. Gene Expression Profiling / methods. Lymphoma, B-Cell / genetics. Mediastinal Neoplasms / genetics
  • [MeSH-minor] Adult. Apoptosis / genetics. Cell Line, Tumor / metabolism. Chromosome Deletion. Female. Gene Amplification. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Janus Kinases / genetics. Janus Kinases / metabolism. Male. Middle Aged. NF-kappa B / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. STAT Transcription Factors / genetics. STAT Transcription Factors / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728785.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / STAT Transcription Factors; EC 2.7.10.2 / Janus Kinases
  •  go-up   go-down


30. Darwiche N, Abou-Lteif G, Bazarbachi A: Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax. Leukemia; 2007 Feb;21(2):261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax.
  • N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic retinoid that inhibits growth of many human tumor cells, including those resistant to natural retinoids.
  • We have previously shown that HPR inhibits proliferation and induces apoptosis of human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia (ATL) and HTLV-I-negative malignant T cells, whereas no effect is observed on normal lymphocytes.
  • In this report, we identified HPR-induced reactive oxygen species (ROS) generation as the key mediator of cell cycle arrest and apoptosis of malignant T cells.
  • HPR treatment of HTLV-I-negative malignant T cells was associated with a rapid and progressive ROS accumulation.
  • Pre-treatment with the antioxidants vitamin C and dithiothreitol inhibited ROS generation, prevented HPR-induced ceramide accumulation, cell cycle arrest, cytochrome c release, caspase-activation and apoptosis.
  • Therefore, anti-oxidants protected malignant T cells from HPR-induced growth inhibition.
  • The expression of the HTLV-I oncoprotein Tax abrogated HPR-induced ROS accumulation in HTLV-I-infected cells, which explains their lower sensitivity to HPR.
  • Defining the mechanism of free radical induction by HPR may support a potential therapeutic role for this synthetic retinoid in ATL and HTLV-I-negative T-cell lymphomas.
  • [MeSH-major] Cell Death / drug effects. Fenretinide / pharmacology. Gene Products, tax / pharmacology. Human T-lymphotropic virus 1. T-Lymphocytes / physiology
  • [MeSH-minor] Anticarcinogenic Agents / pharmacology. Humans. Leukemia, Myeloid, Acute. Reactive Oxygen Species / metabolism. U937 Cells

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122865.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Gene Products, tax; 0 / Reactive Oxygen Species; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


31. Cristofanon S, Morceau F, Scovassi AI, Dicato M, Ghibelli L, Diederich M: Oxidative, multistep activation of the noncanonical NF-kappaB pathway via disulfide Bcl-3/p50 complex. FASEB J; 2009 Jan;23(1):45-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative, multistep activation of the noncanonical NF-kappaB pathway via disulfide Bcl-3/p50 complex.
  • Buthionine sulfoximine (BSO) is a well-known inhibitor of glutathione synthesis, producing slow glutathione (GSH) depletion and oxidative stress; some "responder" cells avoid BSO-induced death by trans-activating the prosurvival protein Bcl-2.
  • Here we show that BSO activates a noncanonical, inhibitory NF-kappaB- and p65-independent NF-kappaB pathway via a multistep process leading to the up-regulation of Bcl-2.
  • The early phase, coinciding with substantial thiol depletion, produces a cytosolic preparative complex, consisting of p50 and its interactor Bcl-3 linked by interprotein disulfide bridges.
  • The late phase, coinciding with reactive oxygen species production, is responsible, probably via p38 activation, for nuclear targeting of the complex and trans-activation of Bcl-2.
  • [MeSH-minor] Buthionine Sulfoximine. Gene Expression Regulation / physiology. Glutathione / metabolism. Humans. I-kappa B Kinase / metabolism. Monocytes / drug effects. Monocytes / metabolism. Oxidation-Reduction. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reactive Oxygen Species. Transcription Factor RelA / genetics. Transcription Factor RelA / metabolism. U937 Cells. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796561.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / NF-kappa B p50 Subunit; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 0 / Transcription Factor RelA; 0 / Transcription Factors; 0 / proto-oncogene protein bcl-3; 5072-26-4 / Buthionine Sulfoximine; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; GAN16C9B8O / Glutathione
  •  go-up   go-down


32. Monaco SE, Angelastro JM, Szabolcs M, Greene LA: The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer; 2007 May 1;120(9):1883-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
  • ATF5, a transcription factor important in differentiation, proliferation and survival, has been found to be highly expressed in neural progenitor cells and in certain tumors including glioblastomas (GBMs), but its expression in other normal and neoplastic tissues has not been extensively investigated.
  • A tissue microarray immunostained for ATF5 showed diffuse nuclear expression (as defined by the presence in greater than 25% of cells) in 63% (117/186) of neoplastic samples, when compared to only 32% (20/62) in nonneoplastic tissues.
  • When analyzed by histologic subtype, a significantly greater proportion of adenocarcinomas, transitional cell carcinomas, squamous cell carcinomas and metastatic carcinomas of various tissue origins had nuclear staining when compared to nonneoplastic tissues.
  • There was no significant difference in ATF5 expression in renal cell carcinomas, lymphomas and seminomas, when compared to nonneoplastic tissues.
  • Past work found that loss of ATF5 function triggers death of GBM cells, but not of normal activated astrocytes.
  • Here, we observed that loss of ATF5 function caused significant apoptotic death of neoplastic breast cell lines, but not of nonneoplastic breast cell lines.
  • Our data demonstrate elevated ATF5 expression in a wide variety of neoplasms and that interference with ATF5 function selectively triggers death of breast carcinoma cells.
  • [MeSH-minor] Adenocarcinoma / chemistry. Apoptosis. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17266024.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATF5 protein, human; 0 / Activating Transcription Factors
  •  go-up   go-down


33. Zhang PH, Zhou XY, Shui RH, Zhang TM, Zheng AH, Guo XH, Zhu XZ: [Detection of t (14; 18) chromosomal translocation in paraffin-embedded tissues of follicular lymphoma and its clinical significance]. Zhonghua Bing Li Xue Za Zhi; 2007 Sep;36(9):600-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of t (14; 18) chromosomal translocation in paraffin-embedded tissues of follicular lymphoma and its clinical significance].
  • OBJECTIVE: To study the genetic aberrations and their pathologic significance in follicular lymphoma (FL).
  • METHODS: Paraffin-embedded tissue samples of 55 cases of FL, 28 cases of other small B-cell lymphomas and 10 cases of reactive follicular hyperplasia were retrieved.
  • Nested polymerase chain reaction (PCR) was used to detect clonal rearrangement of immunoglobulin heavy chain gene (IgH) in FL and other small B-cell lymphomas.
  • As for other small B-cell lymphomas, 25 cases were positive for beta-actin.
  • CONCLUSIONS: The detection rate of clonal IgH rearrangement in FL is lower than that in other small B-cell lymphomas.
  • 18) in paraffin-embedded tissue samples by FISH helps in diagnosis of FL.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Lymphoma, Follicular / genetics. Translocation, Genetic
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Female. Humans. In Situ Hybridization, Fluorescence / methods. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Male. Middle Aged. Paraffin Embedding. Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070448.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


34. Feng ZY, Mo XL, Shao CK, Su ZL: [Expressions of matrix metalloproteinase 9 in mucosal natural killer/T cell and mature T cell lymphomas and its relation to Epstein-Barr virus infection]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep;27(9):1338-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of matrix metalloproteinase 9 in mucosal natural killer/T cell and mature T cell lymphomas and its relation to Epstein-Barr virus infection].
  • OBJECTIVE: To investigate the expression of matrix metalloproteinase 9 (MMP9) in mucosal natural killer/T cell and mature T cell lymphomas and its relation to Epstein-Barr virus (EBV) infection.
  • METHODS: The expression of MMP9 and EBV-encoded RNA (EBER) were detected by immunohistochemistry and in situ hybridization in 59 cases of mucosal natural killer/T cell and mature T cell lymphomas.
  • The positivity rate of EBERs was correlated with histopathological subtype (P<0.05), but not with clinical stage, vascular invasion or the patients' survival time (P>0.05).
  • The expression level of MMP9 was not correlated with the clinical stage, vascular invasion or survival time (P>0.05).
  • CONCLUSION: EBV may play an important role in the development of mucosal natural killer/T cell and mature T cell lymphomas and promote disease progression by up-regulating MMP9 expression indirectly.
  • Elimination of EBV infection may be helpful to prevent the development of lymphoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Herpesvirus 4, Human / physiology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / virology. Matrix Metalloproteinase 9 / metabolism. Mucous Membrane / pathology. Natural Killer T-Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884772.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


35. Chen YH, Gao J, Fan G, Peterson LC: Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol; 2010 Jan;23(1):105-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.
  • Recent studies have shown the nuclear expression of sox11 in mantle cell lymphoma, which raises the question about its possible association with t(11;14)(q13;q32), the genetic hallmark of mantle cell lymphoma leading to the overexpression of cyclin D1.
  • In this study, we examined sox11 expression in 211 cases of B-cell neoplasms by immunohistochemistry, and evaluated its association with t(11;14) and overexpression of cyclin D1.
  • Nuclear staining of sox11 was observed in 54 of 57 (95%) mantle cell lymphomas, including 52 of 53 (98%) classical and 2 of 4 variant types.
  • Two of the three mantle cell lymphomas negative for nuclear sox11 staining were analyzed and were positive for t(11;14).
  • All other B-cell lymphomas (114 cases) showed variable positive staining in the cytoplasm, but no nuclear positivity.
  • Sox11 was then examined in plasma cell myeloma and hairy cell leukemia as a subset of plasma cell myeloma carry t(11;14) and overexpress cyclin D1, and cyclin D1 is overexpressed in a subset of hairy cell leukemia independent of t(11;14).
  • We found no nuclear staining of sox11 in 30 plasma cell myelomas examined, including 12 cases with t(11;14)(q13;q32).
  • It is interesting that intense nuclear staining of sox11 was present in a subset of hairy cell leukemias (5 of 10), and was associated with the overexpression of cyclin D1.
  • Our results indicate that the nuclear expression of sox11 is highly associated with mantle cell lymphoma, but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.
  • Its association with the overexpression of cyclin D1 in hairy cell leukemia suggests that sox11 may be involved in the upregulation of cyclin D1 in this leukemia.
  • [MeSH-major] Cyclin D1 / biosynthesis. Leukemia, Hairy Cell / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Mantle-Cell / metabolism. SOXC Transcription Factors / biosynthesis
  • [MeSH-minor] Cell Nucleus / metabolism. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801969.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SOX11 protein, human; 0 / SOXC Transcription Factors; 136601-57-5 / Cyclin D1
  •  go-up   go-down


36. Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF: The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Laryngoscope; 2010 May;120(5):937-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
  • OBJECTIVES/HYPOTHESIS: Using a retrospective approach, the aim of this study was to confirm the previously described value of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in patients with primary extranodal lymphoma of the head and neck region.
  • Additionally, the clinical significance of the semiquantitative analysis of the standardized uptake value (SUV), its predictive role in the follow-up setting, and its value in detection of synchronous primaries were studied.
  • METHODS: Twenty-six patients with a primary extranodal head and neck lymphoma (22 diffuse large B-cell lymphoma, one Hodgkin's lymphoma, three malignant T-cell lymphomas) were included.
  • We retrospectively evaluated the clinical outcomes according to the maximum standardized uptake values of the primary lesion (SUV(max)) and whether a positron emission tomography/computed tomography (PET/CT) was performed or not in the follow-up studies.
  • It also has application as an instrument for evaluation of follow-up and response to therapy in patients suffering from primary extranodal lymphoma and for detection of secondary malignancies.
  • [MeSH-major] Blood Glucose / metabolism. Hodgkin Disease / radionuclide imaging. Image Processing, Computer-Assisted. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radionuclide imaging. Otorhinolaryngologic Neoplasms / pathology. Otorhinolaryngologic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Aged, 80 and over. Cecal Neoplasms / mortality. Cecal Neoplasms / pathology. Cecal Neoplasms / radionuclide imaging. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radionuclide imaging. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422687.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Yildirim N, Oksüzoğlu B, Budakoğlu B, Vural M, Abali H, Uncu D, Zengin N: Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: report of 3 cases. Hematology; 2005 Oct;10(5):371-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: report of 3 cases.
  • Primary gastrointestinal system lymphomas constitute about one third of all extranodal lymphomas.
  • Duodenal involvement of the lymphoma is a rare condition.
  • Periampullary lymphoma or lymphomatous involvement of ampulla of Vater is even rarer.
  • Since, periampullary lymphoma is not easy to differentiate from epithelial carcinoma of these sites clinically and radiologically, accurate histopathological diagnosis is essential to plan optimal treatment strategy.
  • In this report, we present three cases of duodenal diffuse large cell lymphoma with involvement of ampulla of Vater, two of whom presented with the initial signs of obstructive jaundice.
  • One of the icteric patients was only diagnosed histopathologically following an explorative laparotomy with the initial diagnosis of carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology


38. Nielsen AA, Kjartansdóttir KR, Rasmussen MH, Sørensen AB, Wang B, Wabl M, Pedersen FS: Activation of the brain-specific neurogranin gene in murine T-cell lymphomas by proviral insertional mutagenesis. Gene; 2009 Aug 1;442(1-2):55-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the brain-specific neurogranin gene in murine T-cell lymphomas by proviral insertional mutagenesis.
  • We report here on retroviral activation of the Nrgn gene in tumors induced by the T-cell lymphomagenic SL3-3 murine leukemia virus.
  • We have performed a systematic expression analysis of Nrgn in various mouse tissues and SL3-3 induced T-cell tumors.
  • Furthermore, elevated Nrgn expression was also observed in some T-cell tumors with no detected provirus integrations into this genomic region.
  • The presented data demonstrate that Nrgn can be produced at high levels outside the brain, and suggest a novel oncogenic role in T-cell lymphomas in mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 1998 Dec;28(12):4094-104 [9862345.001]
  • [Cites] J Virol. 1997 Dec;71(12):9796-9 [9371648.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7689-94 [10075657.001]
  • [Cites] Trends Neurosci. 1999 Jan;22(1):12-6 [10088994.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25623-31 [10464298.001]
  • [Cites] J Neurosci Res. 1999 Oct 1;58(1):107-19 [10491576.001]
  • [Cites] J Virol. 2004 Dec;78(23):13216-31 [15542674.001]
  • [Cites] J Neurosci. 2004 Nov 24;24(47):10660-9 [15564582.001]
  • [Cites] J Virol. 2005 Jan;79(1):67-78 [15596802.001]
  • [Cites] Pflugers Arch. 2005 Apr;450(1):1-12 [15806400.001]
  • [Cites] Virology. 2005 Jul 5;337(2):353-64 [15913695.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3546-52 [16051745.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7656-72 [16299527.001]
  • [Cites] Acta Neuropathol. 2006 Jan;111(1):29-38 [16320026.001]
  • [Cites] BMC Cancer. 2006;6:23 [16438728.001]
  • [Cites] J Neurosci. 2006 Jun 7;26(23):6230-7 [16763030.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18680-4 [17121985.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):13-9 [17164770.001]
  • [Cites] Int J Biol Sci. 2007;3(4):212-24 [17389928.001]
  • [Cites] Biochem J. 2007 May 15;404(1):31-43 [17295609.001]
  • [Cites] J Virol. 2009 Jan;83(1):336-46 [18945767.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):229-37 [1824695.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):63-77 [10579912.001]
  • [Cites] J Virol. 2000 Mar;74(5):2161-8 [10666245.001]
  • [Cites] Bioelectrochemistry. 2000 Jun;51(2):163-73 [10910165.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11232-7 [11016969.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1508-10 [11222401.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):153-62 [11223030.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16223-31 [11279107.001]
  • [Cites] Eur J Haematol. 2001 Nov-Dec;67(5-6):332-4 [11872084.001]
  • [Cites] J Leukoc Biol. 2002 May;71(5):731-40 [11994497.001]
  • [Cites] Cancer. 2002 May 1;94(9):2447-53 [12015770.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6559-66 [12242653.001]
  • [Cites] Reproduction. 2002 Dec;124(6):767-74 [12530914.001]
  • [Cites] Adv Cancer Res. 2003;88:53-99 [12665053.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4532-41 [12808095.001]
  • [Cites] Eur J Neurosci. 2003 Jul;18(1):13-22 [12859333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34598-604 [12819200.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D523-7 [14681473.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):170-3 [1688653.001]
  • [Cites] J Neurosci Res. 1990 Aug;26(4):397-408 [2231781.001]
  • [Cites] J Neurosci. 1990 Dec;10(12):3782-92 [2269883.001]
  • [Cites] Neuron. 1992 Jul;9(1):37-44 [1321645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1460-4 [8381968.001]
  • [Cites] J Virol. 1993 Dec;67(12):7118-24 [8230434.001]
  • [Cites] Arch Biochem Biophys. 1995 Jan 10;316(1):335-42 [7840634.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):10314-22 [7730337.001]
  • [Cites] Biol Reprod. 1995 Sep;53(3):579-90 [7578682.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22407-13 [8798403.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):28798-804 [8910523.001]
  • [Cites] J Virol. 1997 Feb;71(2):1196-206 [8995642.001]
  • [Cites] Genomics. 1997 Apr 15;41(2):243-9 [9143500.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1294-300 [9880498.001]
  • (PMID = 19376211.001).
  • [ISSN] 1879-0038
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100266-03; United States / NCI NIH HHS / CA / CA100266-03; United States / NIAID NIH HHS / AI / R01AI41570; United States / NIAID NIH HHS / AI / R01 AI041570; United States / NCI NIH HHS / CA / R01 CA100266; United States / NIAID NIH HHS / AI / AI041570-10; United States / NIAID NIH HHS / AI / R01 AI041570-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nrgn protein, mouse; 132654-77-4 / Neurogranin
  • [Other-IDs] NLM/ NIHMS125977; NLM/ PMC2734486
  •  go-up   go-down


39. Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, Xu ZG, Suzuki D, Tsuji K: Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol; 2006 May;142(5):587-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: In situ hybridization and immunostaining of biopsy specimens; extraction of DNA samples from cutaneous lesions and/or peripheral blood mononuclear cells for EBV DNA assay.
  • RESULTS: T cells positive for EBV-encoded small nuclear RNA (EBER) were detected, to various degrees, in cutaneous infiltrates in 28 (97%) of 29 patients, including all 6 patients with definite HV with a positive phototest reaction, 11 of 12 patients with probable HV without evidence of photosensitivity, and all 11 patients with severe HV associated with systemic symptoms.
  • In addition to EBER-positive T cells, many cytotoxic T lymphocytes expressing T-cell intracellular antigen 1 and granzyme B were present in the cutaneous lesions.
  • Natural killer (NK) cells were absent or at a background level.
  • The UV-induced cutaneous lesions showed histopathologic findings consistent with those of HV, containing many EBER-positive cells.
  • Although no hematologic abnormalities were found in the definite and probable HV groups, the amounts of EBV DNA were increased in the peripheral blood mononuclear cells.
  • By contrast, the severe HV group had markedly increased levels of EBV DNA associated with NK-cell lymphocytosis, and complications including chronic active EBV infection, hypersensitivity to mosquito bites, and hemophagocytic syndrome.
  • Five patients with severe disease died of EBV-associated NK/T-cell lymphomas or hemophagocytic syndrome 2 to 14 years after onset.
  • CONCLUSION: Both typical and severe HV are included within the spectrum of cutaneous disorders mediated by EBV-infected T cells, and the severe HV group may have overt EBV-associated NK/T-cell lymphoproliferative disorders with a frequently fatal outcome.

  • Genetic Alliance. consumer health - Hydroa vacciniforme.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702496.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Epstein-Barr Virus Nuclear Antigens
  •  go-up   go-down


40. Fisher RI: Treatment of diffuse large B-cell lymphomas. Semin Hematol; 2006 Oct;43(4):205-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of diffuse large B-cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Semin Hematol. 2006 Oct;43(4):221-9 [17027656.001]
  • [CommentOn] Semin Hematol. 2006 Oct;43(4):251-61 [17027659.001]
  • [CommentOn] Semin Hematol. 2006 Oct;43(4):240-50 [17027658.001]
  • [CommentOn] Semin Hematol. 2006 Oct;43(4):207-12 [17027654.001]
  • [CommentOn] Semin Hematol. 2006 Oct;43(4):213-20 [17027655.001]
  • [CommentOn] Semin Hematol. 2006 Oct;43(4):230-9 [17027657.001]
  • (PMID = 17027653.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


41. Buza JJ, Burgess SC: Modeling the proteome of a Marek's disease transformed cell line: a natural animal model for CD30 overexpressing lymphomas. Proteomics; 2007 Apr;7(8):1316-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling the proteome of a Marek's disease transformed cell line: a natural animal model for CD30 overexpressing lymphomas.
  • Marek's disease (MD) in the chicken, caused by the highly infectious MD alpha-herpesvirus (MDV), is both commercially important and a unique, naturally occurring model for human T-cell lymphomas overexpressing the Hodgkin's disease antigen, CD30.
  • Proteins were extracted from an MDV-transformed cell line and were then identified using 2-D LC-ESI-MS/MS.
  • The UA-01 proteome is proliferative, differentiated, angiogenic, pro-metastatic and pro-immune-escape but anti-programmed cell death, -anergy, -quiescence and -senescence and is consistent with a cancer phenotype.
  • The cytokines, cytokine receptors, and their related proteins suggest that UA-01 has a regulatory T-cell phenotype.
  • [MeSH-major] Antigens, CD30 / metabolism. Chickens. Disease Models, Animal. Lymphoma, T-Cell / chemistry. Marek Disease. Proteome
  • [MeSH-minor] Animals. Cell Line. Cell Transformation, Neoplastic. Databases, Protein. Humans. Models, Biological. Molecular Sequence Data. Signal Transduction / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443643.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Proteome
  •  go-up   go-down


42. Paterson MA, Hosking PS, Coughlin PB: Expression of the serpin centerin defines a germinal center phenotype in B-cell lymphomas. Am J Clin Pathol; 2008 Jul;130(1):117-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the serpin centerin defines a germinal center phenotype in B-cell lymphomas.
  • Centerin (SERPINA9/GCET1) is a protease inhibitor with expression restricted to germinal center B cells and lymphoid malignancies with germinal center B-cell maturation.
  • Expression of the centerin gene transcript, along with bcl-6 and GCET2/HGAL, constitutes a molecular signature associated with a good prognosis in diffuse large B-cell lymphomas.
  • Centerin expression was demonstrated in Burkitt lymphoma Raji cells.
  • An immunohistochemical survey of normal tissues showed centerin expression in germinal center B cells in lymphoid follicles in tonsil, lymph node, and lymphoid tissue in the gastrointestinal tract.
  • Centerin was strongly expressed in most follicular lymphomas.
  • In addition, 14 (47%) of 30 diffuse large B-cell lymphomas were positive for centerin, which correlated most closely with CD10 expression.
  • Immunohistochemical expression of centerin further defines the germinal center cell origin of a subgroup of lymphomas.
  • [MeSH-major] Germinal Center / metabolism. Lymphoma, B-Cell / metabolism. Serpins / biosynthesis
  • [MeSH-minor] Antibodies, Monoclonal. Cell Line, Tumor. Humans. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Microscopy, Confocal. Microscopy, Fluorescence. Neoplasm Proteins. Phenotype

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550480.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Neoplasm Proteins; 0 / SERPINA9 protein, human; 0 / Serpins
  •  go-up   go-down


43. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther; 2005 Jan;4(1):13-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
  • Overexpression of Bcl-2/Bcl-X(L) protein has been observed in more than 80% of B-cell lymphomas.
  • Diffuse large cell lymphoma (DLCL) is the most common subtype of non-Hodgkin's lymphoma. (-)-Gossypol, a natural product isolated from cottonseeds, was discovered as a potent small-molecule inhibitor of Bcl-2 and Bcl-X(L) proteins, with a Ki value in the nanomole per liter range for both.
  • In vitro, (-)-gossypol showed significant growth inhibition effect against WSU-DLCL2 lymphoma cell line and fresh cells obtained from a lymphoma patient with no effect on normal peripheral blood lymphocytes.
  • As expected (-)-gossypol induced complete cytochrome c release from mitochondria, increased caspases-3 and -9 activity, and caused apoptotic death without affecting protein levels of Bcl-2, Bcl-X(L), Bax, and Bak.
  • The addition of cyclophosphamide-Adriamycin-vincristine-prednisolone (CHOP) regimen to lymphoma cells preexposed to (-)-gossypol enhanced killing significantly.
  • We conclude that adding Bcl-2/Bcl-X(L) small-molecule inhibitor to standard chemotherapy may prove an effective strategy in lymphoma therapy.
  • [MeSH-major] Gossypol / pharmacology. Lymphoma, Large B-Cell, Diffuse / pathology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Apoptosis / drug effects. Caspase 3. Caspase 9. Caspases / metabolism. Cell Division / drug effects. Cell Line, Tumor. Cyclophosphamide / administration & dosage. Cytochromes c. Doxorubicin / administration & dosage. Humans. Mice. Mice, SCID. Prednisone / administration & dosage. Transplantation, Heterologous. Vincristine / administration & dosage. bcl-X Protein

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. Gossypol .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657349.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA22453-20
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Bcl2l1 protein, mouse; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9007-43-6 / Cytochromes c; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp9 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases; KAV15B369O / Gossypol; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


44. Muris JJ, Ylstra B, Cillessen SA, Ossenkoppele GJ, Kluin-Nelemans JC, Eijk PP, Nota B, Tijssen M, de Boer WP, van de Wiel M, van den Ijssel PR, Jansen P, de Bruin PC, van Krieken JH, Meijer GA, Meijer CJ, Oudejans JJ: Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol; 2007 Jan;136(1):38-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.
  • Intrinsic resistance of lymphoma cells to apoptosis is a probable mechanism causing chemotherapy resistance and eventual fatal outcome in patients with diffuse large B cell lymphomas (DLBCL).
  • We investigated whether microarray expression profiling of apoptosis related genes predicts clinical outcome in 46 patients with primary nodal DLBCL.
  • Unsupervised cluster analysis using genes involved in apoptosis (n = 246) resulted in three separate DLBCL groups partly overlapping with germinal centre B-lymphocytes versus activated B-cells like phenotype.
  • One group with poor clinical outcome was characterised by high expression levels of pro-and anti-apoptotic genes involved in the intrinsic apoptosis pathway.
  • A second group, also with poor clinical outcome, was characterised by high levels of apoptosis inducing cytotoxic effector genes, possibly reflecting a cellular cytotoxic immune response.
  • [MeSH-major] Gene Expression Profiling. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062006.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.- / Granzymes
  •  go-up   go-down


45. Kocalka P, Rejman D, Vanek V, Rinnová M, Tomecková I, Králíková S, Petrová M, Páv O, Pohl R, Budesínský M, Liboska R, Tocík Z, Panova N, Votruba I, Rosenberg I: Structural diversity of nucleoside phosphonic acids as a key factor in the discovery of potent inhibitors of rat T-cell lymphoma thymidine phosphorylase. Bioorg Med Chem Lett; 2010 Feb 1;20(3):862-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural diversity of nucleoside phosphonic acids as a key factor in the discovery of potent inhibitors of rat T-cell lymphoma thymidine phosphorylase.
  • Structurally diverse, sugar-modified, thymine-containing nucleoside phosphonic acids were evaluated for their ability to inhibit thymidine phosphorylase (TP, EC 2.4.2.4) purified from spontaneous T-cell lymphomas of an inbred Sprague-Dawley rat strain.
  • [MeSH-major] Lymphoma, T-Cell / enzymology. Nucleosides / chemistry. Organophosphonates / chemistry. Thymidine Phosphorylase / antagonists & inhibitors

  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20053558.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nucleosides; 0 / Organophosphonates; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


46. Salama S: Primary "cutaneous" T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol; 2005 Jun;27(3):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary "cutaneous" T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review.
  • Posttransplantation lymphoproliferative disorders (PTLD) presenting clinically in the skin are rare and usually of B-cell phenotype.
  • Only 7 cases of cutaneous T-cell PTLD have been previously reported, mostly mycosis fungoides type, with no known cases of "cutaneous" presentation by CD30 (Ki-1) anaplastic large cell lymphoma (ALCL).
  • The neoplastic cells were of T-cell phenotype, strongly CD30 with typical staining, and BCL-2 positive, but P53 negative.
  • Twenty-two months following diagnosis, he died of cardiac failure with terminal myocardial infarct.
  • There was however no clinical evidence of systemic spread of the lymphoma.This report adds to the clinical and morphologic spectrum of these rare "cutaneous" lymphomas of T-cell lineage arising in the posttransplantation setting, and suggests that EBV does not play a role in their pathogenesis.
  • [MeSH-major] Immunocompromised Host. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Neutrophils / immunology. Skin Neoplasms / immunology


47. Keller CE, Nandula S, Fisher J, Subramaniyam S, Vakiani E, Savage DG, Murty VV, Alobeid B, Bhagat G: The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations. Am J Clin Pathol; 2008 Aug;130(2):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations.
  • Dual IgH/BCL2 and BCL6 translocations are rarely observed in B-cell non-Hodgkin lymphomas (B-NHLs).
  • We investigated the morphologic, phenotypic, and cytogenetic spectrum of B-NHL with such dual translocations.
  • Dual IgH/BCL2 and BCL6 translocations were detected in follicular lymphomas (FLs) and diffuse large B-cell lymphomas (DLBCLs), representing 6.1% of 132 B-NHLs in our series, including 6 (11%) of 56 FLs (grades 1, 2, and 3a) and 2 (3%) of 76 DLBCLs; 33% of FLs with dual translocations had variant morphologic features.
  • All dual-translocation FLs were CD10+/BCL6+/BCL2+/MUM1-, and the DLBCLs demonstrated "activated" germinal center (CD10+/BCL6+/MUM1+) and non-germinal center (CD10-/BCL6+/MUM1+) phenotypes.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Genes, bcl-2. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / genetics. Proto-Oncogene Proteins c-bcl-6 / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628087.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


48. Georgescu A, Stoicea M, Comănescu M, Dobrea C, Andrei F, Neagu M, Cionca F, Ciobanu A, Lupu A, Ardeleanu C: Prognostic and predictive significance of the bcl-2/IgH translocation in malignant follicular lymphomas. Rom J Morphol Embryol; 2010;51(4):687-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive significance of the bcl-2/IgH translocation in malignant follicular lymphomas.
  • BACKGROUND: The t(14;18) translocation, which leads to an overproduction of the bcl-2 protein, supposedly occurs in almost all follicular lymphomas (FL) and can be detected by FISH methods or by PCR.
  • Its detection is useful in monitoring the response to therapy and in assessing minimal residual disease in bone marrow.
  • AIM: We intended to find significant correlations among morphological features, histological grades, immunohistochemical findings, and cytogenetical aberrations in malignant follicular lymphomas, in order to identify the prognostic and predictive value of the bcl-2/IgH translocation in these malignancies.
  • MATERIAL AND METHODS: We conducted a study on 79 patients with follicular lymphomas.
  • In 66.6% of the cases with t(14;18), the immunohistochemical reaction for bcl-2 protein was positive.
  • A significant positive correlation was found between the IHC positivity for bcl-2 and t(14;18) detected by FISH (p=0.04).
  • CONCLUSIONS: Bcl-2 t(14;18) plays an important role in the pathogenesis of follicular lymphoma.
  • FISH is an important tool in the diagnosis, treatment and follow up of these malignancies, since the immunohistochemical testing is negative in a significant proportion of cases.
  • [MeSH-major] Genes, Immunoglobulin Heavy Chain. Genes, bcl-2. Lymphoma, Follicular / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103627.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


49. Gibson SE, Hsi ED: Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol; 2009 May;40(5):653-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype.
  • Epstein-Barr virus-positive B-cell lymphoproliferative disorders similar to those seen in posttransplantation patients have recently been described in immunocompetent, elderly Asian individuals.
  • The clinicopathologic features of 6 Epstein-Barr virus-positive B-cell lymphomas of the elderly from 5 patients 60 years and older were reviewed.
  • Three specimens exhibited a polymorphous infiltrate with Reed-Sternberg-like cells.
  • The remaining specimens resembled conventional diffuse large B-cell lymphoma.
  • Most tumor cells were Epstein-Barr virus-positive by in situ hybridization and had a nongerminal center B-cell immunophenotype.
  • In addition, 90 cases of diffuse large B-cell lymphoma in patients 60 years and older were screened for Epstein-Barr virus and were negative.
  • Epstein-Barr virus-positive B-cell lymphomas of the elderly occur uncommonly at a United States tertiary medical center.
  • Pathologic features that may aid in identification and trigger Epstein-Barr virus testing include a polymorphic infiltrate, plasmacytic morphology, Reed-Sternberg-like cells, angioinvasion, necrosis, and a nongerminal center B-cell immunophenotype.
  • Further investigation is needed to determine if Epstein-Barr virus status plays an independent role in the prognosis of diffuse large B-cell lymphoma in non-Asian countries, which would also impact the need to screen all diffuse large B-cell lymphoma in older patients for Epstein-Barr virus.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / pathology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology
  • [MeSH-minor] Aged. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Herpesvirus 4, Human. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Tissue Array Analysis. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144386.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


50. Tzekov Ch, Spiriev T, Hristova S, Chernikova S, Minkin K, Naydenov E, Bussarsky V, Romansky K, Marinov M, Kalev O, Cekov A, Laleva L, Kolarov D, Tanova R, Enchev V: [Orbital lymphoma]. Khirurgiia (Sofiia); 2009;(4-5):19-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital lymphoma].
  • INTRODUCTION: Orbital lymphomas are neoplasms with increasing incidence in recent years in immunocompromised, as well as immunocompetent patients, which defines their social importance.
  • MATERIAL AND METHODS: Fourteen patients (8 females, 6 males - 13 primary orbital lymphomas, 1 systemic lymphoma).
  • Mean age at diagnosis was 65.6 years (from 50 to 80 years).
  • Seven cases the diagnosis was made 6 months from the onset of symptoms, 5 cases - 1 year and 2 cases - more than one year.
  • The most common clinical symptoms were exophthalmus (12 case), tumor or bulging mass of the eyelid - 8, diplopy - 6, decreased visual acuity - 5.
  • The diagnosis was made by neuro-ophthalmologist and precised with the aid of CT and MRI.
  • On histological examination, a high grade lymphoma was established in 2 cases with primary orbital lymphoma and one case with systemic lymphoma.
  • All other cases were diagnosed as low-grade B-call small lymphocytic non-Hodgkin's lymphoma.
  • Long-term survival (over 5 years) was observed in 4 cases with primary lymphoma, whereas the patient with systemic form of the disease died 10 months after the operation.
  • [MeSH-major] Lymphoma / pathology. Lymphoma / surgery. Orbital Neoplasms / pathology. Orbital Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Neurosurgical Procedures. Survival Analysis

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20506800.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


51. Li Z, Zhao J, Li Q, Yang W, Song Q, Li W, Liu J: KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Cell Stress Chaperones; 2010 Nov;15(6):905-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway.
  • K562 cells and peripheral blood mononuclear cells were treated with hydrogen peroxide (H(2)O(2)) to determine the expression of Krüppel-like factor (KLF) 4.
  • A full-length complementary DNA or an anti-sense oligonucleotide of KLF4 was transfected into cells, and expressions of B-cell lymphoma/leukemia-2 (bcl-2) and bcl-2-associated X (bax) proteins were analyzed.
  • The results showed that H(2)O(2) treatment of cells resulted in an increase in KLF4 levels; KLF4 induced apoptosis and slowed cell growth, potentially resulting from up-regulation of bax and down-regulation of bcl-2.
  • Transcriptional activities on bcl-2 and bax were promoted following KLF4 overexpression potentially through KLF4 binding sites on corresponding promoters.
  • All results indicate that KLF4 induces apoptosis in leukemia cells involving the bcl-2/bax pathway during H(2)O(2) stimulation, suggesting a potential mechanism for research on drug-induced apoptosis.
  • [MeSH-major] Apoptosis. Kruppel-Like Transcription Factors / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Binding Sites. Caspase 3 / metabolism. Female. Humans. Hydrogen Peroxide / toxicity. K562 Cells. Middle Aged. Promoter Regions, Genetic. Signal Transduction

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 May 4;473(1):95-100 [10802067.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1201-4 [11050388.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5259-69 [11077443.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):1-6 [11123355.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29299-306 [11375995.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 22;308(2):251-6 [12901861.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48004-11 [12970361.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3838-43 [15172991.001]
  • [Cites] Blood. 1975 Mar;45(3):321-34 [163658.001]
  • [Cites] Cell Prolif. 1991 Mar;24(2):203-14 [2009322.001]
  • [Cites] J Immunol Methods. 1993 Feb 26;159(1-2):93-100 [8445268.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):5957-65 [7565748.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4901-9 [9389707.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33750-8 [9837963.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2671-8 [10194447.001]
  • [Cites] Leuk Lymphoma. 1999 May;33(5-6):499-509 [10342577.001]
  • [Cites] Cell Res. 2005 Feb;15(2):92-6 [15740636.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23003-12 [16717086.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 26;362(3):575-81 [17719562.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):6137-49 [17827213.001]
  • [Cites] Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Dec;32(6):1002-6 [18182717.001]
  • [Cites] Shock. 2008 Sep;30(3):260-6 [18197146.001]
  • (PMID = 20401760.001).
  • [ISSN] 1466-1268
  • [Journal-full-title] Cell stress & chaperones
  • [ISO-abbreviation] Cell Stress Chaperones
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; BBX060AN9V / Hydrogen Peroxide; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC3024064
  •  go-up   go-down


52. Miyamoto S, Liu R, Hung S, Wang X, Lam KS: Screening of a one bead-one compound combinatorial library for beta-actin identifies molecules active toward Ramos B-lymphoma cells. Anal Biochem; 2008 Mar 1;374(1):112-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of a one bead-one compound combinatorial library for beta-actin identifies molecules active toward Ramos B-lymphoma cells.
  • This method identified small molecule ligands that bound beta-actin present in cytoplasmic cell extracts of Ramos B-lymphoma cells.
  • These small molecule ligands were resynthesized in immobilized and soluble forms and tested for binding of beta-actin present in Ramos B-cell extracts and for activity against Ramos lymphoma cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Dec;8(12):1167-82 [11755396.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3314-8 [8159745.001]
  • [Cites] J Am Chem Soc. 2002 Jul 3;124(26):7678-80 [12083920.001]
  • [Cites] J Am Chem Soc. 2003 May 21;125(20):6180-8 [12785850.001]
  • [Cites] Acc Chem Res. 2003 Jun;36(6):370-7 [12809522.001]
  • [Cites] Biochemistry. 1994 Dec 13;33(49):14825-33 [7993909.001]
  • [Cites] J Immunol Methods. 1995 Mar 27;180(2):219-23 [7714336.001]
  • [Cites] Int J Pept Protein Res. 1995 Jun;45(6):587-92 [7558590.001]
  • [Cites] Anticancer Drug Des. 1997 Apr;12(3):145-67 [9154108.001]
  • [Cites] Mol Divers. 1996 Oct;2(1-2):57-63 [9238634.001]
  • [Cites] Methods Mol Biol. 1998;87:7-12 [9523254.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):948-55 [15573116.001]
  • [Cites] J Pept Res. 2005 Jan;65(1):130-8 [15686543.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):439-47 [16285906.001]
  • [Cites] Nat Chem Biol. 2006 Jul;2(7):381-9 [16767086.001]
  • [Cites] J Comb Chem. 2006 Jul-Aug;8(4):562-70 [16827569.001]
  • [Cites] Biomacromolecules. 2006 Nov;7(11):3037-46 [17096529.001]
  • [Cites] Biopolymers. 2006;84(6):595-604 [17041919.001]
  • [Cites] Bioconjug Chem. 2007 Jan-Feb;18(1):175-82 [17226971.001]
  • [Cites] Cell Signal. 2007 Aug;19(8):1621-32 [17553668.001]
  • [Cites] J Am Chem Soc. 2003 Nov 19;125(46):13995-4004 [14611236.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):862-76 [15078817.001]
  • [Cites] J Am Chem Soc. 2004 May 12;126(18):5740-9 [15125667.001]
  • [Cites] J Am Chem Soc. 2004 Nov 3;126(43):14095-104 [15506774.001]
  • [Cites] Int J Pept Protein Res. 1991 Jun;37(6):487-93 [1917305.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):82-4 [1944576.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):84-6 [1719428.001]
  • [Cites] Comb Chem High Throughput Screen. 2002 Feb;5(1):83-91 [11860343.001]
  • (PMID = 18023409.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA099136-02; United States / NCI NIH HHS / CA / R33 CA099136-03; United States / NCI NIH HHS / CA / R01 CA098116; United States / NCI NIH HHS / CA / R33 CA099136-01; United States / NCI NIH HHS / CA / CA098116; United States / NCI NIH HHS / CA / CA099136; United States / NCI NIH HHS / CA / CA099136-02; United States / NCI NIH HHS / CA / R33 CA099136; United States / NCI NIH HHS / CA / CA099136-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Peptide Library
  • [Other-IDs] NLM/ NIHMS40764; NLM/ PMC2770001
  •  go-up   go-down


53. Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N: Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer; 2009 Oct 1;115(19):4540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
  • BACKGROUND: Bortezomib demonstrated promising activity in lymphomas.
  • The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma.
  • There were 6 partial responses and 2 patients with progressive disease.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Lymphoma, B-Cell / drug therapy. Pyrazines / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 American Cancer Society.
  • (PMID = 19593797.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


54. Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S: Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol; 2007 Sep;82(3):576-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells.
  • A recent report revealed that a large population of Hodgkin's lymphoma-infiltrating lymphocytes (HLILs) consisted of regulatory T cells.
  • In this study, we cocultured CD4+ naive T cells with KM-H2, which was established as a Hodgkin's Reed-Sternberg cell line, to clarify their ability to induce CD25+ Forkhead box P3+ (Foxp3+) T cells.
  • The characteristic analyses of T cells cocultured with KM-H2 revealed the presence of CD4+CD25+ T cells.
  • Conversely, KM-H2 also generated CD4+ CTLs, which expressed Granzyme B and T cell intracellular antigen-1 in addition to Foxp3+ T cells.
  • In conclusion, KM-H2 promotes a bidirectional differentiation of CD4+ naive T cells toward Foxp3+ T cells and CD4+ CTLs.
  • In addition to KM-H2, several cell lines that exhibit the APC function were able to generate Foxp3+ T cells and CD4+ CTLs.
  • Conversely, the APC nonfunctioning cell lines examined did not induce both types of cells.
  • Our findings suggest that the APC function of tumor cells is essential for the differentiation of CD4+ naive T cells into CD25+Foxp3+ T cells and CD4+ CTLs and at least partly explains the predominance of CD25+Foxp3+ T cells in HLILs and their contribution to a better prognosis.
  • Therefore, in APC-functioning tumors, including classical Hodgkin lymphomas, which generate Foxp3+ T cells and CD4+ CTLs, these T cell repertories play a beneficial role synergistically in disease stability.
  • [MeSH-major] CD4-Positive T-Lymphocytes / cytology. Cell Differentiation / physiology. Forkhead Transcription Factors / metabolism. Interleukin-2 Receptor alpha Subunit / metabolism. Reed-Sternberg Cells / physiology. T-Lymphocytes, Cytotoxic / cytology
  • [MeSH-minor] Cell Proliferation. Cells, Cultured. Gene Expression Regulation. Humans. Interferon-gamma / metabolism. Interleukin-10 / metabolism. Transduction, Genetic

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545218.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


55. Hebeda KM, Van Altena MC, Rombout P, Van Krieken JH, Groenen PJ: PCR clonality detection in Hodgkin lymphoma. J Hematop; 2009 Mar;2(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCR clonality detection in Hodgkin lymphoma.
  • B-cell clonality detection in whole tissue is considered indicative of B-cell non-Hodgkin lymphoma (NHL).
  • We tested frozen tissue of 24 classical Hodgkin lymphomas (cHL) with a varying tumor cell load with the multiplex polymerase chain reaction (PCR) primer sets for IGH and IGK gene rearrangement (BIOMED-2).
  • Using the IGK-VJ and IGK-DE PCRs, an additional six cases had a dominant clonal cell population, resulting in a detection rate of 79% in frozen tissue.
  • There was no evidence of B-cell lymphoma during follow-up of 1 to 6 years and no correlation was found between the presence of a clonal result and Epstein-Barr virus in the tumor cells.
  • Our results indicate that the present routine PCR methods are sensitive enough to detect small numbers of malignant cells in cHL.
  • Therefore, the presence of a clonal B-cell population does not differentiate between cHL and NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1443-50 [10666223.001]
  • [Cites] Diagn Mol Pathol. 2008 Jun;17(2):65-72 [18382369.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1338-43 [17613763.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] Leukemia. 2006 Jan;20(1):176-9 [16307010.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Pathol. 1997 Apr;181(4):387-93 [9196435.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Blood. 1994 Aug 1;84(3):708-15 [8043859.001]
  • [Cites] J Clin Pathol. 1993 Oct;46(10):940-2 [8227413.001]
  • [Cites] J Clin Pathol. 1993 Apr;46(4):337-40 [8388407.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):679-85 [9237178.001]
  • (PMID = 19669221.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713492
  •  go-up   go-down


56. Sekikawa T, Takahara S, Suzuki H, Takeda N, Yamada H, Horiguchi-Yamada J: Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas. Eur J Haematol; 2007 Mar;78(3):264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas.
  • Richter's syndrome occurs in 5-10% of patients with chronic lymphocytic leukemia, either by transformation of the primary neoplastic lymphocyte, or as a distinct B-cell neoplasm.
  • We report a Japanese patient with lymphoplasmacytic lymphoma in whom a diffuse large B-cell lymphoma developed after treatment with rituximab.
  • Molecular examination on immunoglobulin VH genes revealed that the lymphomas had arisen in two separate clones.
  • We reviewed clinical case reports in literature, and found 30-40% of cases with Richter's syndrome and composite lymphoma had a second B-cell lymphoma of a different origin.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253969.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger
  • [Number-of-references] 32
  •  go-up   go-down


57. Gualco G, Chioato L, Van Den Berg A, Weiss LM, Bacchi CE: Composite lymphoma: EBV-positive classic Hodgkin lymphoma and peripheral T-cell lymphoma: a case report. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite lymphoma: EBV-positive classic Hodgkin lymphoma and peripheral T-cell lymphoma: a case report.
  • Composite lymphomas are rare and defined as hematopoietic neoplasms with more than 1 malignant lymphomatous clone showing different phenotypic features.
  • Of all possible combinations between non-Hodgkin lymphomas, B cell or T cell, and Hodgkin lymphoma, the least frequent are the ones combining T-cell non-Hodgkin lymphoma and classic Hodgkin lymphoma.
  • A cervical lymph node biopsy revealed a composite lymphoma with classic Hodgkin lymphoma and peripheral T-cell lymphoma components.
  • The patient refused treatment and died of disease progression 2 months after diagnosis.
  • The biopsied lymph node showed 2 distinct populations, one composed of large cells including typical Reed-Sternberg cells and their variants, with expression of CD30, CD15, PAX5, and LMP-1.
  • The other component was more abundant and comprised polymorphic medium-sized cells with convoluted nuclei; CD3, CD5, CD2, and CD4 expression; and negativity for CD30, cytotoxic granules, and B-cell markers.
  • Epstein-Barr virus DNA of subtype A was identified only in the Hodgkin cells.
  • Clonal T-cell receptor gamma and beta gene rearrangements were detected in the T-cell component, whereas monoclonal immunoglobulin H gene rearrangement was found in the Hodgkin cells.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115485.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


58. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL: In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood; 2006 May 15;107(10):3940-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.
  • In solid tumors, leukemias, and lymphomas, increased frequencies of functional CD4+CD25(high) regulatory T cells (T(reg) cells) have been previously demonstrated.
  • In healthy individuals, T(reg) cells consist not only of memory but also of naive T cells, which can undergo peripheral expansion and are characterized by a relative enrichment for autoreactive T-cell receptors.
  • Here, we demonstrate in patients with premalignant monoclonal gammopathy of undetermined significance and patients with multiple myeloma that functional FoxP3(+) T(reg) cells of naive, central, and effector memory phenotype as determined by CCR7 and CD45RA expression are significantly expanded.
  • Low frequencies of T-cell receptor excision circles in naive T(reg) cells in both healthy controls and multiple myeloma patients point to peripheral expansion as the prominent mechanism of increased frequencies of naive T(reg) cells in these cancer patients.
  • These findings strongly suggest that the increase of functional T(reg) cells in cancer patients is a response to the process of malignant transformation.
  • [MeSH-minor] Antigens, CD / blood. Antigens, CD / genetics. Antigens, CD45 / blood. Antigens, CD45 / genetics. Flow Cytometry. Humans. Receptors, Antigen, T-Cell / blood. Receptors, Antigen, T-Cell / immunology. Receptors, CCR7. Receptors, Chemokine / blood. Receptors, Chemokine / genetics

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410445.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CCR7 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, CCR7; 0 / Receptors, Chemokine; 0 / Receptors, Interleukin-2; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


59. Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT, Rao VK: Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood; 2010 Oct 7;116(14):e35-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphadenopathy in children for which no infectious or malignant cause can be ascertained constitutes a challenging diagnostic dilemma.
  • Autoimmune lymphoproliferative syndrome (ALPS) is a human genetic disorder of lymphocyte apoptosis resulting in an accumulation of lymphocytes and childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias, and an increased risk of B-cell lymphoma.
  • In 1999, investigators at the National Institutes of Health (NIH) suggested criteria to establish the diagnosis of ALPS.
  • Since then, with approximately 500 patients with ALPS studied worldwide, significant advances in our understanding of the disease have prompted the need for revisions to the existing diagnostic criteria and classification scheme.
  • The rationale and recommendations outlined here stem from an international workshop held at NIH on September 21 and 22, 2009, attended by investigators from the United States, Europe, and Australia engaged in clinical and basic science research on ALPS and related disorders.
  • It is hoped that harmonizing the diagnosis and classification of ALPS will foster collaborative research and better understanding of the pathogenesis of autoimmune cytopenias and B-cell lymphomas.

  • Genetic Alliance. consumer health - Autoimmune Lymphoproliferative Syndrome.
  • Genetics Home Reference. consumer health - autoimmune lymphoproliferative syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 15;95(10):3176-82 [10807785.001]
  • [Cites] Blood. 2010 Jun 24;115(25):5164-9 [20360470.001]
  • [Cites] Nature. 2002 Sep 26;419(6905):395-9 [12353035.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):131-5 [14657953.001]
  • [Cites] N Engl J Med. 2004 Sep 30;351(14):1409-18 [15459302.001]
  • [Cites] J Pediatr. 1967 Jun;70(6):891-9 [4165068.001]
  • [Cites] Clin Genet. 1974;5(5):379-86 [4852259.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):314-7 [1372394.001]
  • [Cites] J Clin Invest. 1992 Aug;90(2):334-41 [1386609.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1347-9 [7539157.001]
  • [Cites] Cell. 1995 Jun 16;81(6):935-46 [7540117.001]
  • [Cites] J Clin Invest. 1996 Sep 1;98(5):1107-13 [8787672.001]
  • [Cites] Lancet. 1996 Sep 14;348(9029):719-23 [8806292.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1341-8 [9028957.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2871-9 [9108407.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1541-50 [9811346.001]
  • [Cites] Ann Intern Med. 1999 Apr 6;130(7):591-601 [10189330.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):1002-14 [10090885.001]
  • [Cites] Annu Rev Immunol. 1999;17:221-53 [10358758.001]
  • [Cites] Cell. 1999 Jul 9;98(1):47-58 [10412980.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2575-82 [10515860.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2443-8 [15542578.001]
  • [Cites] Science. 2005 Mar 4;307(5714):1465-8 [15746428.001]
  • [Cites] Hematology. 2006 Feb;11(1):15-23 [16522544.001]
  • [Cites] Annu Rev Immunol. 2006;24:321-52 [16551252.001]
  • [Cites] Haematologica. 2006 Apr;91(4):538-41 [16537120.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1306-12 [16627752.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8953-8 [17517660.001]
  • [Cites] BMC Med Genet. 2007;8:41 [17605793.001]
  • [Cites] Curr Protoc Immunol. 2004 May;Chapter 3:Unit 3.17 [18432928.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3027-30 [19176318.001]
  • [Cites] J Clin Invest. 2009 Oct;119(10):2976-89 [19759517.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2142-5 [20068224.001]
  • [Cites] Immunity. 2010 Mar 26;32(3):291-5 [20346767.001]
  • [Cites] J Allergy Clin Immunol. 2010 Apr;125(4):946-949.e6 [20227752.001]
  • [Cites] Pediatr Clin North Am. 2000 Dec;47(6):1291-310 [11130997.001]
  • (PMID = 20538792.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Consensus Development Conference, NIH; Journal Article; Practice Guideline; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953894
  •  go-up   go-down


60. Chen Y, Sternberg P, Cai J: Characterization of a Bcl-XL-interacting protein FKBP8 and its splice variant in human RPE cells. Invest Ophthalmol Vis Sci; 2008 Apr;49(4):1721-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a Bcl-XL-interacting protein FKBP8 and its splice variant in human RPE cells.
  • PURPOSE: The immunophilin protein FKBP8 interacts with Bcl2/Bcl-XL and is essential for mouse eye development.
  • The purpose of this study was to define the expression of the FKBP8 gene in cultured human RPE cells and explore its involvement in the control of apoptosis.
  • METHODS: Rapid amplification of cDNA ends (RACE) was performed on RNA isolated from human RPE cells.
  • The interaction between Bcl-XL and FKBP8 was measured by coimmunoprecipitation.
  • ARPE-19 cells stably overexpressing FKBP8 and its splice variant were established.
  • Their responses to thapsigargin and t-butyl hydroperoxide-induced cell death were measured by flow cytometry.
  • The activities of the nuclear factor of activated T cells (NFAT) were measured by reporter assay after transient transfection.
  • RESULTS: RACE and RT-PCR identified a splice variant of FKBP8 lacking exons 3, 4, and 5 in human RPE cells.
  • Both the full-length and the short form of FKBP8 proteins showed mitochondrial distribution and directly interacted with Bcl-XL.
  • CONCLUSIONS: FKBP8 and its novel splice variant are Bcl-XL-interacting proteins and regulate the apoptotic signaling pathways in the RPE.

  • Hazardous Substances Data Bank. TERT-BUTYL HYDROPEROXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biochem. 2007 Jan;295(1-2):153-65 [16874461.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C45-51 [16943242.001]
  • [Cites] Retina. 2007 Mar;27(3):269-75 [17460581.001]
  • [Cites] Curr Opin Genet Dev. 2007 Jun;17(3):228-33 [17467263.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3846-53 [17652760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12565-70 [17636122.001]
  • [Cites] Am J Med. 1999 Nov;107(5):489-506 [10569305.001]
  • [Cites] Prog Retin Eye Res. 2000 Mar;19(2):205-21 [10674708.001]
  • [Cites] Curr Med Chem. 2000 Jul;7(7):731-48 [10702636.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Mar;41(3):645-55 [10711676.001]
  • [Cites] Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34 [11033038.001]
  • [Cites] Trends Plant Sci. 2001 Sep;6(9):426-31 [11544132.001]
  • [Cites] Prog Retin Eye Res. 2001 Nov;20(6):705-32 [11587915.001]
  • [Cites] Arch Ophthalmol. 2001 Oct;119(10):1439-52 [11594943.001]
  • [Cites] Curr Opin Pharmacol. 2002 Feb;2(1):82-6 [11786313.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33242-8 [12032145.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):411-31 [12208254.001]
  • [Cites] Arch Ophthalmol. 2002 Nov;120(11):1435-42 [12427055.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):15-20 [12469180.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):28-37 [12510191.001]
  • [Cites] Genomics. 2004 Jan;83(1):181-92 [14667822.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2004 Mar;31(3):119-28 [15008953.001]
  • [Cites] Ophthalmologica. 2004 May-Jun;218(3):202-6 [15103217.001]
  • [Cites] Development. 2004 May;131(9):2149-59 [15105374.001]
  • [Cites] Am J Ophthalmol. 1975 Jul;80(1):1-23 [808131.001]
  • [Cites] Eye (Lond). 1988;2 ( Pt 5):552-77 [2476333.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4701-14 [8402648.001]
  • [Cites] J Biol Chem. 1993 Nov 5;268(31):22992-9 [7693682.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2468-71 [8162596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1784-8 [7533300.001]
  • [Cites] Gene. 1995 Jul 28;160(2):297-302 [7543869.001]
  • [Cites] Nature. 1998 Jan 29;391(6666):489-92 [9461216.001]
  • [Cites] Arch Ophthalmol. 1998 Feb;116(2):203-9 [9488273.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):29905-11 [10514472.001]
  • [Cites] FEBS Lett. 2005 Feb 28;579(6):1469-76 [15733859.001]
  • [Cites] FEBS Lett. 2005 Mar 14;579(7):1591-6 [15757646.001]
  • [Cites] Hum Mol Genet. 2005 Jul 1;14(13):1889-902 [15905180.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2688-99 [15990872.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):30-8 [16176796.001]
  • [Cites] Surv Ophthalmol. 2006 Mar-Apr;51(2):137-52 [16500214.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2709-15 [16723490.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1409-18 [16729032.001]
  • [Cites] Cell Stress Chaperones. 2006 Autumn;11(3):199-207 [17009592.001]
  • [Cites] EMBO J. 2006 Oct 18;25(20):5015-25 [17024179.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:143-83 [17029566.001]
  • [Cites] Cell Mol Life Sci. 2006 Dec;63(24):2889-900 [17075696.001]
  • [Cites] Mol Cell. 2007 Jan 26;25(2):193-205 [17244528.001]
  • (PMID = 18385096.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY007892-17; United States / NEI NIH HHS / EY / R01 EY007892; United States / NIEHS NIH HHS / ES / ES014668; United States / NIEHS NIH HHS / ES / R21 ES014668; United States / NEI NIH HHS / EY / EY007892-17; United States / NEI NIH HHS / EY / EY08126; United States / NIEHS NIH HHS / ES / R21 ES014668-02; United States / NEI NIH HHS / EY / P30 EY008126; United States / NIEHS NIH HHS / ES / ES014668-02; United States / NEI NIH HHS / EY / EY07892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / FKBP8 protein, human; 0 / NFATC Transcription Factors; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / bcl-X Protein; 67526-95-8 / Thapsigargin; 955VYL842B / tert-Butylhydroperoxide; EC 5.2.1.- / Tacrolimus Binding Proteins
  • [Other-IDs] NLM/ NIHMS124227; NLM/ PMC2715170
  •  go-up   go-down


66. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M: FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol; 2007 Oct;18(10):1685-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in T-cell and NK-cell neoplasms.
  • BACKGROUND: A growing number of studies demonstrate the utility of (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) in the management of malignant lymphoma.
  • The results of FDG-PET, however, have not been studied extensively for T-cell and natural killer (NK)-cell neoplasms.
  • PATIENTS AND METHODS: We retrospectively evaluated pretreatment FDG-PET scans in 41 patients with T/NK-cell neoplasms diagnosed according to the World Health Organization (WHO) classification.
  • Histological subtypes frequently included were peripheral T-cell lymphoma, unspecified (PTCLu, n = 11), extranodal NK/T-cell lymphoma, nasal type (ENKL, n = 8), primary cutaneous anaplastic large cell lymphoma (C-ALCL, n = 5), and angioimmunoblastic T-cell lymphoma (AILT, n = 4).
  • RESULTS: FDG-PET detected a lymphoma lesion in at least one site in 36 out of 41 patients.
  • The positive rate was equally high in most histological subtypes except for cutaneous lymphomas: PTCLu 91%, ENKL 100%, C-ALCL 60%, AILT 100%.
  • CONCLUSION: T/NK-cell neoplasms incorporated in this study were generally FDG-avid except for cutaneous lesions and bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716987.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


67. Beà S, Campo E: Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica; 2008 May;93(5):641-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] B-Lymphocytes / cytology. B-Lymphocytes / metabolism. Cell Proliferation. Cluster Analysis. Disease Progression. Genome. Humans. Immune System. Lymphoma / genetics. Models, Biological. Models, Genetic. Nucleic Acid Hybridization. Translocation, Genetic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2008 May;93(5):680-7 [18367489.001]
  • [CommentOn] Haematologica. 2008 May;93(5):670-9 [18367492.001]
  • [CommentOn] Haematologica. 2008 May;93(5):688-96 [18367485.001]
  • (PMID = 18450732.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Editorial; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


68. Tapinassi C, Micucci C, Lahortiga I, Malazzi O, Gasparini P, Gorosquieta A, Odero MD, Belloni E: A novel t(2;3)(p11;q27) in a case of follicular lymphoma. Cancer Genet Cytogenet; 2007 Jan 1;172(1):70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel t(2;3)(p11;q27) in a case of follicular lymphoma.
  • Rearrangement of the BCL6 gene is found in follicular lymphomas and in diffuse large B cell lymphomas of follicular center cell origin.
  • [MeSH-major] Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 3 / genetics. Lymphoma, Follicular / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Aged. Gene Rearrangement. Humans. Immunoglobulins / genetics. Male. Polymerase Chain Reaction. Proto-Oncogene Proteins c-bcl-6 / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175383.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IgK; 0 / Immunoglobulins; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


69. Nie K, Zhang T, Allawi H, Gomez M, Liu Y, Chadburn A, Wang YL, Knowles DM, Tam W: Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol; 2010 Sep;177(3):1470-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.
  • PRDM1/Blimp-1, a master regulator for B cell terminal differentiation, is a putative tumor suppressor in diffuse large B cell lymphomas (DLBCL).
  • Inactivating mutations of PRDM1 have been previously identified in a subset of nongerminal center B cell-like (GCB) DLBCL.
  • We investigated the presence of alternative mechanisms of down-regulating PRDM1 in a cohort of 25 primary DLBCL and six DLBCL cell lines.
  • While some DLBCL, predominantly the GCB-type, showed low levels of both PRDM1alpha mRNA and protein, presumably as a result of direct transcription repression, discordant expressions between the two were identified in a subset of DLBCL without PRDM1 mutations, the primarily non-GCB type, consistent with translational down-regulation.
  • Let-7, in particular let-7b, is overexpressed in DLBCL relative to normal GCB cells, suggesting that it is deregulated.
  • These findings provide further evidence for an important role of impairment of terminal B cell differentiation in DLBCL pathogenesis.
  • [MeSH-major] Down-Regulation / genetics. Epigenesis, Genetic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. MicroRNAs / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 May 15;107(10):4090-100 [16424392.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8256-64 [17220301.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):728-38 [17724137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14988-93 [17846422.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9762-70 [17942906.001]
  • [Cites] Methods. 2008 Jan;44(1):3-12 [18158127.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2488-9; author reply 2489-90 [18263789.001]
  • [Cites] Annu Rev Immunol. 2008;26:133-69 [18370921.001]
  • [Cites] Curr Opin Immunol. 2008 Jun;20(3):259-64 [18554885.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):242-52 [18583325.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jul;67(7):720-7 [18596541.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):3083-90 [18818519.001]
  • [Cites] Carcinogenesis. 2008 Nov;29(11):2073-7 [18700235.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3754-64 [19047678.001]
  • [Cites] Blood. 2009 May 7;113(19):4586-94 [19202128.001]
  • [Cites] Immunity. 2009 May;30(5):744-52 [19446474.001]
  • [Cites] Nature. 2009 Aug 13;460(7257):909-13 [19578360.001]
  • [Cites] Mol Cell Biol. 2009 Nov;29(21):5813-27 [19737919.001]
  • [Cites] J Immunol. 2009 Nov 1;183(9):5778-87 [19828640.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3890-8 [19717648.001]
  • [Cites] J Immunol. 2009 Dec 1;183(11):7039-46 [19915049.001]
  • [Cites] Immunity. 2009 Dec 18;31(6):941-52 [20064451.001]
  • [Cites] Nat Immunol. 2010 Feb;11(2):114-20 [20084069.001]
  • [Cites] Int J Cancer. 2010 Mar 15;126(6):1316-26 [19530237.001]
  • [Cites] Endocr Relat Cancer. 2010 Mar;17(1):F19-36 [19779035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4664-8 [20176957.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):169-76 [11248811.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Immunity. 2003 Oct;19(4):607-20 [14563324.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] RNA. 2004 Jul;10(7):1153-61 [15208450.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):967-77 [15492122.001]
  • [Cites] Cell. 1994 Apr 22;77(2):297-306 [8168136.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Pathol. 2005 May;206(1):76-86 [15772984.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]
  • [Cites] Nat Immunol. 2006 May;7(5):466-74 [16565720.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):773-82 [16767092.001]
  • (PMID = 20651244.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Repressor Proteins; 0 / mirnlet7 microRNA, human; 138415-26-6 / PRDM1 protein, human
  • [Other-IDs] NLM/ PMC2928978
  •  go-up   go-down


70. Haque SA, Shad A, Ozdemirli M, Shanmugam VK, Kallakury B: A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis. Pediatr Rep; 2009;1(1):e3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis.
  • Primary lymphoma of the bone (PLB) accounts for 2% of all non-Hodgkin's lymphomas, and until recently it had not been well characterized in literature.
  • Had a biopsy not been performed the diagnosis would have been missed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):200-2 [18315931.001]
  • [Cites] Korean J Intern Med. 2002 Sep;17(3):191-7 [12298430.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):154-60 [16782988.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):47-54 [17145622.001]
  • [Cites] Jpn J Clin Oncol. 2007 Mar;37(3):216-23 [17472971.001]
  • [Cites] Clin Orthop Relat Res. 2007 Sep;462:11-9 [17496555.001]
  • [Cites] Can Assoc Radiol J. 1989 Apr;40(2):75-9 [2702504.001]
  • (PMID = 21589819.001).
  • [ISSN] 2036-749X
  • [Journal-full-title] Pediatric reports
  • [ISO-abbreviation] Pediatr Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3096024
  • [Keywords] NOTNLM ; adolescent. / bone pain / chronic recurrent multifocal osteomyelitis / primary lymphoma of bone
  •  go-up   go-down


71. Ody C, Jungblut-Ruault S, Cossali D, Barnet M, Aurrand-Lions M, Imhof BA, Matthes T: Junctional adhesion molecule C (JAM-C) distinguishes CD27+ germinal center B lymphocytes from non-germinal center cells and constitutes a new diagnostic tool for B-cell malignancies. Leukemia; 2007 Jun;21(6):1285-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Junctional adhesion molecule C (JAM-C) distinguishes CD27+ germinal center B lymphocytes from non-germinal center cells and constitutes a new diagnostic tool for B-cell malignancies.
  • Differentiation of naïve B cells into plasma cells or memory cells occurs in the germinal centers (GCs) of lymph follicles or alternatively via a GC- and T-cell-independent pathway.
  • It is currently assumed that B-cell lymphomas correlate to normal B-cell differentiation stages, but the precise correlation of several B-cell lymphomas to these two pathways remains controversial.
  • In the present report, we describe the junctional adhesion molecule C (JAM-C), currently identified at the cell-cell border of endothelial cells, as a new B-cell marker with a tightly regulated expression during B-cell differentiation.
  • Expression of JAM-C in tonsils allows distinction between two CD27+ B-cell subpopulations: JAM-C- GC B cells and JAM-C+ non-germinal B cells.
  • The expression of JAM-C in different B-cell lymphomas reveals a disease-specific pattern and allows a clear distinction between JAM-C- lymphoproliferative syndromes (chronic lymphocytic leukemia, mantle cell lymphoma and follicular lymphoma) and JAM-C+ ones (hairy cell leukemia, marginal zone B-cell lymphoma).
  • Therefore, we propose JAM-C as a new identification tool in B-cell lymphoma diagnosis.
  • [MeSH-major] Antigens, CD27. B-Lymphocytes / cytology. Cell Adhesion Molecules / analysis. Germinal Center / cytology. Leukemia, B-Cell / diagnosis. Lymphoma, B-Cell / diagnosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429428.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / JAM3 protein, human
  •  go-up   go-down


72. Campbell LJ: Cytogenetics of lymphomas. Pathology; 2005 Dec;37(6):493-507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of lymphomas.
  • Cytogenetic analysis is now a routine part of the diagnosis and management of a significant number of lymphoid malignancies.
  • Whilst conventional cytogenetics remains the most comprehensive method for assessing chromosome abnormalities, the technical difficulties associated with conventional cytogenetics in most lymphomas has resulted in increased use of fluorescence in situ hybridisation (FISH) to identify specific abnormalities that are useful in either the diagnosis or management of these disorders.
  • The finding of one of the Burkitt's translocations is of major importance in the diagnosis of Burkitt's and Burkitt's-like lymphomas, whereas the t(14;18), although seen in most follicular lymphomas (FL), is not usually required to make a diagnosis.
  • Conventional cytogenetics may be useful for identifying markers of resistance to Helicobacter pylori therapy in MALT lymphomas.
  • In disorders such as Hodgkin lymphoma, hairy cell leukaemia and lymphoplasmacytoid lymphoma, although many cytogenetic abnormalities have been observed, no consistent or specific abnormalities have been identified and so, at this point in our knowledge of the genetics of these disorders, cytogenetics cannot be considered a useful test for either diagnosis or prognosis.
  • In contrast, the diagnosis of mantle cell lymphoma is now dependent upon the identification of the 11;14 translocation that results in cyclin D1 up-regulation.
  • It is widely acknowledged that FISH is the most consistently useful test to identify the juxtaposition of the CCND1 and IGH genes in mantle cell lymphoma and is regarded as the 'gold standard'.
  • FISH also has a role in identifying genetic abnormalities of prognostic significance in chronic lymphocytic leukaemia.
  • Given the wealth of genetic and cytogenetic abnormalities that are continuing to be found in chronic lymphoid malignancies, it will be some time before the optimal use of both conventional cytogenetics and FISH is established in the diagnosis and management of lymphomas.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Lymphoma / diagnosis. Lymphoma / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Humans

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373229.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 141
  •  go-up   go-down


73. Chen ZY, Zhou XY, Zhang TM, Hong XN, Yin JL, Hu XC, Shi DR: [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
  • OBJECTIVE: To explore the feasibility of semi-nested PCR technique for detection of immunoglobulin heavy chain (IgH) clonal rearrangement in bone marrow of B-cell lymphoma patient and to further evaluate its clinicopathological value.
  • METHODS: Gene clonal rearrangement of IgH was detected by semi-nested PCR using primers of FR2 & FR3A in 105 bone marrow samples of patients with B-cell lymphoma.
  • RESULTS: Among 105 cases of B-cell lymphoma, bone marrow involvement was detected by PCR technique in 48 cases (45.7%), while only 22 cases (21.0%) were detected by bone marrow cytological analysis.
  • The incidence of bone marrow involvement at the time of initial diagnosis detected by PCR technique was 30.8% for diffuse large B cell lymphoma (DLBCL), 25.0% for follicular lymphoma (FL), and 100.0% for small lymphocytic lymphoma (SLL), respectively.
  • Rate of clonal IgH gene rearrangement by PCR in early B-cell lymphoma was lower than that in advanced stage B-cell lymphoma patients (P = 0.02).
  • CONCLUSION: Semi-nested PCR analysis may be an effective method for detection of abnormalities in bone marrow in patients with B-cell lymphoma and is superior to cytomorphology.
  • [MeSH-major] Bone Marrow / pathology. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Immunoglobulin Heavy Chains / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy / methods. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615255.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


74. Jiang TB, Li X, Zhou J, Zhou Y, Yuan H, Xiang H, Yang GP, Lü HW, Xing XW, Liu J: [Expression of PDCD5 in multiple myeloma and its relation with BCL-2]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep;33(9):814-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PDCD5 in multiple myeloma and its relation with BCL-2].
  • OBJECTIVE: To determine the expression of apoptosis related gene PDCD5 in multiple myeloma (MM), and to analyze the relation between PDCD5 and BCL-2.
  • METHODS: The expressions of PDCD5 and BCL-2 protein and mRNA were determined by immunohistochemical staining method, flow cytometry (FCM) and reverse transcription polymerase chain reaction (RT-PCR) method in bone marrow mononuclear cells.
  • We also analyzed the relation between PDCD5 and BCL-2.
  • RESULTS: Immunohistochemical staining showed that PDCD5 protein positive cell percentage, staining intensity index (SII) of PDCD5 protein, BCL-2 protein positive cell percentage, and SII of BCL-2 protein were (34.75 +/- 6.49)%, (281.16 +/- 75.33), (29.97 +/- 5.57)%, and (224.94 +/- 57.72) in the MM group and (52.98 +/- 5.84)%, (462.84 +/- 39.77), (5.56 +/- 1.95)%, and (27.84 +/- 9.75) in the control group (all P < 0.05).
  • RT-PCR showed that relative expression of PDCD5 and BCL-2 mRNA were (0.33 +/ -0.07) and (0.33 +/- 0.08) in the MM group and (0.53 +/- 0.05) and (0.12 +/- 0.02) in the control group (all P < 0.05).
  • The positive cell percentage of PDCD5 and BCL-2 protein was negative correlation (r = -0.86, P < 0.05); the expression of PDCD5 and BCL-2 mRNA was the same status (r = -0.90, P < 0.05).
  • CONCLUSION: The expressions of PDCD5 protein and mRNA in MM patients are down-regulated, but the expressions of BCL-2 protein and mRNA are up-regulated.
  • The mRNA and protein expression of PDCD5 and BCL-2 has negative correlation.
  • [MeSH-major] Apoptosis / genetics. Apoptosis Regulatory Proteins / biosynthesis. Multiple Myeloma / genetics. Neoplasm Proteins / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Female. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812660.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / PDCD5 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  •  go-up   go-down


75. Terui Y: [Molecular target drugs for malignant lymphoma]. Nihon Rinsho; 2010 Oct;68(10):1881-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular target drugs for malignant lymphoma].
  • According to revised WHO classification for lymphoid malignancies, biological differences among pathological subtypes of lymphomas could be key points for molecular target therapies.
  • For B cell lymphomas, CD20, CD22, CD19 can be molecules for target therapies, whereas there are not so many molecular targets in T cell lymphomas yet.
  • Especially, inhibitors for mTOR, IKK/JAK, HDAC, proteasome, HSP90, and proapoptotic molecules are developing in clinical trials for B cell- and T cell-lymphomas, and their anti-lymphoma activities will be considerably promising.
  • Moreover, immunomodulatory drugs such as lenalidomide are also tried to investigate the effect on lymphomas.
  • Here, some novel molecular drugs currently under development will be reviewed about their anti-lymphoma effects.
  • [MeSH-major] Lymphoma / drug therapy. Molecular Targeted Therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954334.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


76. Becker PD, Legrand N, van Geelen CM, Noerder M, Huntington ND, Lim A, Yasuda E, Diehl SA, Scheeren FA, Ott M, Weijer K, Wedemeyer H, Di Santo JP, Beaumont T, Guzman CA, Spits H: Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice. PLoS One; 2010;5(10)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Passive transfer of antibodies not only provides immediate short-term protection against disease, but also can be exploited as a therapeutic tool.
  • The immortalization of human B cells represents an alternative for obtaining human mAbs, but relies on the availability of biological samples from vaccinated individuals or convalescent patients.
  • In this work we describe a novel approach to generate fully human mAbs by combining a humanized mouse model with a new B cell immortalization technique.
  • METHODOLOGY/PRINCIPAL FINDINGS: After transplantation with CD34+CD38⁻ human hematopoietic progenitor cells, BALB/c Rag2⁻/⁻IL-2Rγc⁻/⁻ mice acquire a human immune system and harbor B cells with a diverse IgM repertoire.
  • Sorted human CD19+CD27+ B cells were retrovirally transduced with the human B cell lymphoma (BCL)-6 and BCL-XL genes, and subsequently cultured in the presence of CD40-ligand and IL-21.
  • This procedure allows generating stable B cell receptor-positive B cells that secrete immunoglobulins.
  • We recovered stable B cell clones that produced IgM specific for tetanus toxoid and the hepatitis B surface antigen, respectively.
  • [MeSH-minor] Animals. Cell Line, Transformed. Cell Separation. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Mice. Mice, Inbred BALB C

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2004 Aug;10(8):871-5 [15247913.001]
  • [Cites] Science. 2004 Apr 2;304(5667):104-7 [15064419.001]
  • [Cites] Mol Immunol. 1991 Dec;28(12):1317, 1319-20 [1749380.001]
  • [Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3647-54 [15191950.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3886-93 [15319293.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):303-13 [15711548.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1065-72 [16151393.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15951-6 [17038503.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1316-22 [17057712.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):118-30 [17259968.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):705-14 [17389241.001]
  • [Cites] Immunity. 2007 May;26(5):537-41 [17521579.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1075-7 [17921981.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1134-43 [17921999.001]
  • [Cites] Virology. 2007 Dec 5;369(1):143-52 [17707071.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1313-23 [17982459.001]
  • [Cites] Int Immunol. 2008 Jan;20(1):105-16 [18032374.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4805-15 [18354204.001]
  • [Cites] Methods Mol Biol. 2008;415:65-82 [18370148.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4293-6 [18270327.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;324:95-107 [18481455.001]
  • [Cites] Nature. 2008 May 29;453(7195):667-71 [18449194.001]
  • [Cites] Curr Opin Immunol. 2008 Aug;20(4):460-70 [18656541.001]
  • [Cites] J Infect Dis. 2008 Sep 1;198(5):673-82 [18627269.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):2033-42 [18695003.001]
  • [Cites] Adv Immunol. 2008;98:151-224 [18772006.001]
  • [Cites] J Exp Med. 2009 Jan 16;206(1):25-34 [19103877.001]
  • [Cites] J Exp Med. 2009 Jun 8;206(6):1423-34 [19487422.001]
  • [Cites] Cell Host Microbe. 2009 Jul 23;6(1):5-9 [19616761.001]
  • [Cites] J Immunol. 2009 Dec 15;183(12):7645-55 [19923447.001]
  • [Cites] Nat Med. 2010 Jan;16(1):123-8 [20023635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7 [20615947.001]
  • [Cites] PLoS One. 2010;5(8):e12009 [20700454.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2053-8 [16455958.001]
  • [Cites] Nat Med. 2000 Jan;6(1):103-6 [10613834.001]
  • [Cites] Immunol Today. 2000 May;21(5):204-6 [10782048.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):681-6 [11914273.001]
  • [Cites] J Exp Med. 2003 Apr 7;197(7):939-45 [12682112.001]
  • [Cites] Curr Opin Mol Ther. 2003 Apr;5(2):172-9 [12772508.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • (PMID = 20957227.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / F32 AI063846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin M
  • [Other-IDs] NLM/ PMC2949385
  •  go-up   go-down


77. Kovrigina AM, Probatova NA: [Morphoimmunohistochemical differential diagnosis of B-cell lymphomas]. Arkh Patol; 2006 May-Jun;68(3):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphoimmunohistochemical differential diagnosis of B-cell lymphomas].
  • The paper considers the stages of B-cell differentiation at the level of central (bone marrow) and peripheral (lymph node) organs of the immune system.
  • The immunophenotype of B-cell lymphoid tumors and their "normal" cell analogues was compared, by taking into account 4 stages of B-cell differentiation: bone marrow B-cell precursors, mature B-cell, B-cell with follicular differentiation, postfollicular B-cell.
  • Algorithms of immunohistochemical differential diagnosis of B-cell lymphomas are proposed when their morphological patterns are similar.
  • [MeSH-major] Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Antigens, Differentiation / analysis. B-Lymphocytes / immunology. Cell Differentiation / immunology. Diagnosis, Differential. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830626.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Lectures
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Differentiation
  •  go-up   go-down


78. Saqi A, Yun SS, Yu GH, Alexis D, Taub RN, Powell CA, Borczuk AC: Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn Cytopathol; 2005 Aug;33(2):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD138 (Syndecan-1) is a transmembrane heparan sulfate proteoglycan present on the surface of plasma cells and epithelial cells.
  • We characterized CD138 expression in cell-block preparations of fluids/effusions, focusing on the distinction between carcinoma and mesothelioma.
  • One hundred formalin-fixed, paraffin-embedded cell-block sections of fluids/effusions consisting of 58 metastatic carcinomas, 24 mesotheliomas, 11 reactive mesothelial cell proliferations, 3 lymphomas, 3 metastatic sarcomas, and 1 metastatic melanoma were stained with a monoclonal antibody against CD138.
  • CD138 staining was observed in 32/58 (55%) metastatic carcinomas and 2/24 (8%) mesotheliomas; all reactive mesothelial cells, lymphomas, sarcomas, and melanoma were negative.
  • CD138 is a highly specific marker in the differential diagnosis of carcinoma vs. mesothelioma.
  • Distinct membranous staining without background staining of most inflammatory cells makes CD138 an ideal marker for cell-block preparations of fluids/effusions.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma / diagnosis. Membrane Glycoproteins / analysis. Mesothelioma / diagnosis. Mesothelioma / metabolism. Proteoglycans / analysis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Neoplasm Metastasis. Predictive Value of Tests. Syndecan-1. Syndecans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007640.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


79. Lo SC, Hannink M: PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. J Biol Chem; 2006 Dec 8;281(49):37893-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex.
  • The N terminus of the PGAM5 protein contains a conserved NXESGE motif that binds to the substrate binding pocket in the Kelch domain of Keap1, whereas the C-terminal PGAM domain binds Bcl-X(L).
  • The identification of PGAM5 as a novel substrate of Keap1 suggests that Keap1 regulates both transcriptional and post-transcriptional responses of mammalian cells to oxidative stress.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Ubiquitin-Protein Ligases / metabolism
  • [MeSH-minor] Amino Acid Motifs. Amino Acid Sequence. Animals. Autoantigens. Binding Sites. COS Cells. Cell Line. Cercopithecus aethiops. Humans. Membrane Proteins. Molecular Sequence Data. Oxidation-Reduction. Phylogeny. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Sequence Homology, Amino Acid. Substrate Specificity. Transfection. bcl-X Protein / genetics. bcl-X Protein / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046835.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / R01 AT003899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Cell Cycle Proteins; 0 / GOLGA4 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / KEAP1 protein, human; 0 / Membrane Proteins; 0 / Recombinant Proteins; 0 / bcl-X Protein; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


80. Cannizzo E, Sohani AR, Ferry JA, Hochberg EP, Kluk MJ, Dorn ME, Sadowski C, Bucci JJ, Ackerman AM, Longtine JA, Carulli G, Preffer FI: Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors. J Hematop; 2009;2(3):163-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors.
  • Multiple malignancies may occur in the same patient, and a few reports describe cases with multiple hematologic and non-hematologic neoplasms.
  • We report the case of a patient who showed the sequential occurrence of four different lymphoid neoplasms together with a squamous cell carcinoma of the lung.
  • A 62-year-old man with adenopathy was admitted to the hospital, and lymph node biopsy was positive for low-grade follicular lymphoma.
  • Two years later, a PET-CT scan showed a left hilar mass in the lung; biopsy showed a squamous cell carcinoma.
  • Simultaneously, he was diagnosed with diffuse large B cell lymphoma in a neck lymph node; after chemo- and radiotherapy, he achieved a complete response.
  • A restaging PET-CT scan 2 years later revealed a retroperitoneal nodule, and biopsy again showed a low-grade follicular lymphoma, while a biopsy of a cutaneous scalp lesion showed a CD30-positive peripheral T cell lymphoma.
  • After some months, a liver biopsy and a right cervical lymph node biopsy showed a CD30-positive peripheral T cell lymphoma consistent with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
  • Flow cytometry and cytogenetic and molecular genetic analysis performed at diagnosis and during the patient's follow-up confirmed the presence of two clonally distinct B cell lymphomas, while the two T cell neoplasms were confirmed to be clonally related.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1079-82 [12423812.001]
  • [Cites] J Chemother. 2003 Aug;15(4):406-8 [12962371.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1489-97 [17372278.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):239-42 [9700587.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):161-8 [10194134.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):123-7 [10966173.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):997-1005 [11592772.001]
  • [Cites] Rinsho Ketsueki. 1986 Dec;27(12):2313-8 [3573322.001]
  • (PMID = 20309424.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2766444
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Cytogenetics / Diffuse large B cell lymphoma / Follicular lymphoma / Multiple malignancies / Risk factors
  •  go-up   go-down


81. Trcić RL, Sustercić D, Kuspilić M, Jelić-Puskarić B, Fabijanić I, Kardum-Skelin I: Recurrent chromosomal abnormalities in lymphomas in fine needle aspirates of lymph node. Coll Antropol; 2010 Jun;34(2):387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent chromosomal abnormalities in lymphomas in fine needle aspirates of lymph node.
  • The detection of specific chromosomal abnormalities is important in the diagnostic workup of aggressive lymphomas, giving its impact on the treatment strategies and prognosis.
  • This has been accomplished by using the fluorescent in situ hybridisation method (FISH) performed on fine needle aspiration (FNA) specimens what is attractive in the diagnosis of lymphoma in the comparation with other methods for collecting samples.
  • The cytogenetic analyses were performed in series of 80 patients with lymphoma (43 women and 37 men, median age 48, range 3-90 years).
  • In our series 89.0% (71) of the specimens yield sufficient numbers of analysable metaphases, comprising 63 non-Hodgkin lymphomas (NHL) and 8 examples of Hodgkin disease (HD).
  • Four abnormal clones detected in Hodgkin disease were typically consisted of a small percentage of metaphases.
  • [MeSH-major] Chromosome Aberrations / classification. Lymph Nodes / pathology. Lymphoma / genetics. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Biopsy, Needle / methods. Female. Gene Rearrangement / genetics. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. Male. Middle Aged. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698107.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


82. Alvarez Alvarez C, Vieites Pérez-Quintela B, Pesqueira Santiago D, Santos Armentia E, San Miguel Fraile P, Antón Badiola I: [Primary non-Hodgkin large B-cell lymphoma of bladder. Report of a case]. Actas Urol Esp; 2005 Oct;29(9):902-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin large B-cell lymphoma of bladder. Report of a case].
  • [Transliterated title] Linfoma no hodgkin B de célula grande primario de vejiga. Presentación de un caso.
  • INTRODUCTION: primary genitourinary lymphomas are uncommon.
  • Among them, bladder lymphomas are extremely unusual tumors, with clinico-radiological features similar to urothelial carcinomas of bladder.
  • Histopathological, immunohistochemical and molecular studies are compulsory for the diagnosis.
  • CLINICAL CASE: An 80-year-old woman was admitted to our hospital with hematuria.
  • After transuretral biopsy, a diagnosis of non-Hodgkin large B-cell lymphoma was made.
  • Neither clinical symptoms nor radiological findings showed disseminated disease, indicating that the tumor was localized in the bladder.
  • After chemotherapy, the patient is disease-free after 9 months follow-up.
  • COMMENT: if a bladder tumor with uncommon histopathological features is found, lymphoma should be excluded, because chemotherapy avoids cystectomy.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Urinary Bladder Neoplasms


83. Bekker V, Scherpbier H, Beld M, Piriou E, van Breda A, Lange J, van Leth F, Jurriaans S, Alders S, Wertheim-van Dillen P, van Baarle D, Kuijpers T: Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. J Infect Dis; 2006 Nov 1;194(9):1323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents.
  • Epstein-Barr virus (EBV) is a widespread, persistent herpesvirus that can transform B cells and that is associated with malignant lymphomas.
  • Frequencies of interferon-gamma-producing EBV-specific CD8+ T cells were comparable with those in healthy control children, and antibodies to EBV nuclear antigen were detected in 73% of EBV-seropositive children.
  • Detectable EBV DNA load was not correlated with HIV-1 RNA level or with CD4+ T cell count increase after the start of HAART.
  • EBV DNA was found not only in the CD19+ B cell fraction but also--at stable levels--in the CD4+ and CD8+ T cell fractions.
  • Although the reason for the aberrant T cell tropism of EBV remains unclear, these data may provide an explanation for the differential EBV dynamics in the presence of normal serological findings.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041860.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / DNA, Viral
  •  go-up   go-down


84. Tauber S, Nerlich A, Lang S: MALT lymphoma of the paranasal sinuses and the hard palate: report of two cases and review of the literature. Eur Arch Otorhinolaryngol; 2006 Jan;263(1):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALT lymphoma of the paranasal sinuses and the hard palate: report of two cases and review of the literature.
  • Extra-nodal low-grade B-cell lymphomas arising in the gastrointestinal tract recapitulate the structure and features of mucosa-associated lymphoid tissue, called "MALT lymphomas."
  • In the head and neck region except for the salivary glands the occurrence of this neoplasm is very rare.
  • The authors report on two such cases of MALT lymphoma, one of the hard palate in a 71-year-old woman and the other of the paranasal sinuses in a 69-year-old woman with the history of chronic sinusitis.
  • Such chronic inflammatory conditions can induce the development of MALT lymphoma.
  • Clinical elaboration should include computerized tomography (CT) and magnetic resonance imaging (MRI) for the assessment of tumor extension, bone destruction, lymph node involvement and differentiation of mucosal thickening from tumor mass.
  • Biopsy for histopathological diagnosis is mandatory.
  • Treatment should be surgery, irradiation or combined radio-chemotherapy depending on the stage of the disease.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Maxillary Sinus Neoplasms / diagnosis. Palatal Neoplasms / diagnosis. Palate, Hard

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Osteopath Assoc. 1993 Feb;93(2):252, 255-8 [8432674.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Verh Dtsch Ges Pathol. 1992;76:14-23 [1283245.001]
  • [Cites] Acta Radiol Oncol. 1986 Mar-Apr;25(2):91-7 [3012963.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Ann Rheum Dis. 2005 Mar;64(3):471-3 [15708896.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Apr;103(4 Pt 1):294-300 [8154771.001]
  • [Cites] Head Neck Surg. 1981 Jul-Aug;3(6):490-9 [6265409.001]
  • [Cites] J Laryngol Otol. 1994 Mar;108(3):263-5 [8169517.001]
  • [Cites] Cancer. 1974 Feb;33(2):555-62 [4812772.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):268-79 [1996731.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(5):399-405 [2499096.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):292-3 [4130475.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Sep;100(3):334-9 [16122662.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2888-93 [1375527.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):342-51 [1690952.001]
  • [Cites] Pathologe. 2004 Feb;25(1):63-72 [14767614.001]
  • [Cites] Radiology. 1988 Jun;167(3):803-8 [3363145.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(3):235-40 [1900969.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Laryngol Otol. 1994 Nov;108(11):995-7 [7829959.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1438-44 [2306688.001]
  • (PMID = 16320028.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Rega MF, Reed JC, Pellecchia M: Robust lanthanide-based assays for the detection of anti-apoptotic Bcl-2-family protein antagonists. Bioorg Chem; 2007 Apr;35(2):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robust lanthanide-based assays for the detection of anti-apoptotic Bcl-2-family protein antagonists.
  • Anti-apoptotic Bcl-2-family proteins (Bcl-2, Bcl-x(L), Bfl-1, Mcl-1, Bcl-W and Bcl-B) have been recently validated as drug discovery targets for cancer, owed to their ability to confer tumor resistance to chemotherapy or radiation.
  • The anti-apoptotic activity of Bcl-2 proteins is due to their ability to heterodimerize with their pro-apoptotic counterparts (proteins such as Bad, Bim or Bid) via a conserved peptide region termed BH3.
  • Thus, molecules that mimic pro-apoptotic BH3 domains represent a direct approach to overcoming the protective effects of anti-apoptotic proteins such as Bcl-2 and Bcl-x(L).
  • Here, we report on the development and evaluation of two novel Lanthanide-based assays that are formatted for high-throughput screening of small molecules capable of antagonizing BH3-Bcl-2 interactions.
  • These assays represent useful tools to enable further studies in the search for novel, safe and effective anti-cancer agents targeting Bcl-2-family proteins.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. BH3 Interacting Domain Death Agonist Protein / antagonists & inhibitors. Lanthanoid Series Elements / chemistry. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996562.001).
  • [ISSN] 0045-2068
  • [Journal-full-title] Bioorganic chemistry
  • [ISO-abbreviation] Bioorg. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 113318; United States / NCI NIH HHS / CA / CA 2062202; United States / NCI NIH HHS / CA / CA 2080901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / Lanthanoid Series Elements; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


86. Robillard N, Pellat-Deceunynck C, Bataille R: Phenotypic characterization of the human myeloma cell growth fraction. Blood; 2005 Jun 15;105(12):4845-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of the human myeloma cell growth fraction.
  • In this study we quantified the proliferation rate of normal and malignant plasma cells (PCs) by ex vivo incorporation of 5-bromo-2'-deoxyuridine (BrdU; labeling index, LI) using flow cytometry.
  • We show that all bone marrow PCs, either normal or malignant, include a subset of proliferating PCs present within the CD45(bright) fraction.
  • Indeed, medullary normal and malignant PCs were always heterogeneous for CD45 expression, and proliferation was always restricted primarily to the CD45(bright) compartment.
  • Moreover, an inverse correlation was found between LI or CD45 and B-cell lymphoma 2 (Bcl-2) in both malignant and normal PCs, the most proliferating CD45(bright) PCs have the lowest Bcl-2 expression.
  • Among all of these molecules, only CD11a was exclusively expressed by CD45(bright) proliferating myeloma cells.
  • In conclusion, proliferating myeloma cells are characterized by the specific CD45(bright) CD11a(pos) Bcl-2(low) phenotype.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Antigens, CD11a / biosynthesis. Antigens, CD45 / biosynthesis. Antigens, CD45 / metabolism. Apoptosis. Bone Marrow Cells / cytology. Bromodeoxyuridine / pharmacology. Cell Proliferation. Cell Separation. Coloring Agents / pharmacology. Flow Cytometry. Humans. Leukocytes, Mononuclear / cytology. Leukocytes, Mononuclear / metabolism. Palatine Tonsil / cytology. Palatine Tonsil / metabolism. Phenotype. Plasma Cells / metabolism. Proto-Oncogene Proteins c-bcl-2 / chemistry. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741217.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD11a; 0 / Coloring Agents; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.1.3.48 / Antigens, CD45; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


87. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res; 2006 Dec 1;12(23):7174-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: CD52 is a GPI-linked glycoprotein expressed by B cells, T cells, monocytes, and macrophages.
  • The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
  • RESULTS: The vast majority of low-grade B cell lymphoproliferative disorders (CLL/small lymphocytic leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and mucosa-associated lymphoid tissue lymphomas) express CD52.
  • In addition, we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen.
  • In contrast, there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas, with 25% of cases of diffuse large B cell lymphoma and Burkitt lymphoma demonstrating no detectable CD52.
  • In addition, the majority of neoplasms of the T cell lineage are negative for the antigen, including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma, anaplastic large cell lymphoma, and peripheral T cell lymphoma, not otherwise specified.
  • Finally, the vast majority of cases of acute myeloid leukemia, Hodgkin lymphoma, and multiple myeloma are negative for CD52 expression.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Glycoproteins / biosynthesis. Leukemia, Myeloid. Lymphoma, B-Cell. Lymphoma, T-Cell. Lymphoproliferative Disorders
  • [MeSH-minor] Acute Disease. Antibodies, Monoclonal, Humanized. Humans. Immunohistochemistry. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145843.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


88. Chang CM, Schroeder JC, Huang WY, Dunphy CH, Baric RS, Olshan AF, Dorsey KC, Dent GA, Cerhan JR, Lynch CF, Rothman N, Cantor KP, Blair A: Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study. Leuk Res; 2010 Feb;34(2):190-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study.
  • We used fluorescence in situ hybridization (FISH) assays to identify t(14;18) translocations in archival paraffin-embedded tumor sections from non-Hodgkin lymphoma (NHL) cases enrolled in a population-based study. t(14;18) was identified in 54% of 152 cases, including 39% of diffuse large cell lymphomas (26 of 66 cases) and 84% of follicular lymphomas (36 of 43 cases).
  • Eighty-seven percent of t(14;18)-positive cases and 57% of t(14;18)-negative cases expressed bcl-2.
  • FISH assays detected twice as many t(14;18)-positive follicular lymphomas as PCR assays.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):73-9 [12742158.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):154-9 [12953811.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]
  • [Cites] Pathology. 2004 Feb;36(1):19-44 [14757555.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 1;150(1):22-6 [15041219.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Histopathology. 2004 Nov;45(5):501-10 [15500654.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):675-8 [3470542.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1137-44 [3473254.001]
  • [Cites] Am J Public Health. 1988 May;78(5):570-1 [3354743.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Arch Environ Health. 1991 Mar-Apr;46(2):70-4 [2006896.001]
  • [Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5522s-5528s [1394167.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5529s-5540s [1394168.001]
  • [Cites] Am J Ind Med. 1993 Feb;23(2):301-12 [8427258.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):963-9 [8622046.001]
  • [Cites] Blood Cells Mol Dis. 1998 Mar;24(1):62-72 [9616042.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):77-82 [15723651.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1067-73 [16006802.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Eur J Haematol. 2006 Apr;76(4):284-93 [16519699.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):198-204 [16671111.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1027-33 [16680153.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1363-9 [16621961.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):652-9 [17204518.001]
  • [Cites] Leuk Res. 2008 May;32(5):737-42 [17964648.001]
  • [Cites] Cancer Causes Control. 2008 Oct;19(8):859-67 [18386141.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5456s-5462s; discussion 5462s-5464s [1394154.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):85-94 [10564590.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1189-207 [10583924.001]
  • [Cites] Br J Haematol. 2001 May;113(2):383-90 [11380403.001]
  • [Cites] Epidemiology. 2001 Nov;12(6):701-9 [11679800.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):159-68 [11936822.001]
  • [Cites] Leukemia. 2003 Jan;17(1):255-9 [12529690.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • (PMID = 19505720.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R21 CA107966-01; United States / NICHD NIH HHS / HD / R24 HD050924; United States / NCI NIH HHS / CA / R03 CA71617-01; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NCI NIH HHS / CA / CA107966-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ NIHMS157999; NLM/ PMC2815151
  •  go-up   go-down


89. Jezersek Novaković B, Vovk M, Juznic Setina T: A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003. Ann Hematol; 2006 Dec;85(12):849-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
  • Primary gastric lymphomas are the most common extranodal non-Hodgkin's lymphomas and are divided into indolent (low grade) and aggressive (high grade) types.
  • They are mainly the disease of middle age, with a male predominance reported by most of the studies.
  • For several years, surgery played a central role in diagnosis, staging, and treatment of this entity, yet recently there has been a move away from a surgical approach to conservative treatment.
  • To determine the role of surgery as the initial treatment modality, we performed this retrospective single-center research on 245 patients with primary gastric lymphoma who were treated according to our protocol between 1990 and 2003.
  • The patients' characteristics, distribution of histological types, treatment results, and disease-specific survival were followed.
  • According to the histology, 59.2% had diffuse large B-cell lymphoma (DLCL), 26.1% MALT lymphoma, 9.8% mixed lymphoma (indolent and aggressive at the same time), while other types were infrequent.
  • In total, 161 patients (65.7%) were treated with surgical resection as the initial treatment, which was then followed or not by additional therapy (chemotherapy, chemotherapy and radiotherapy, radiotherapy) depending on the histological type of lymphoma and the extent of residual disease after surgery.
  • The selection of treatment (chemotherapy, chemotherapy and radiotherapy, radiotherapy or Helicobacter pylori eradication only) was based on the histological type of lymphoma, considering also the patients' physical condition.
  • The disease-specific survival in the group of patients who underwent surgery was statistically significantly better than in patients who were treated conservatively (p=0.049).
  • However, the results were biased, as the patients who were treated conservatively were either in a worse performance status or presented with a more extensive disease.
  • Similarly, in the DLCL type the disease-specific survival was better in the surgically treated group (97.2%) than in the conservatively treated patients (89.2%).
  • The difference was barely significant (p=0.046) and again the results have to be considered with caution due to the selection of patients in a worse performance status or with a more extensive disease for conservative treatment.
  • In the MALT lymphoma and mixed lymphoma types, there were no differences in the disease-specific survival between both treatment groups.
  • [MeSH-major] Lymphoma / mortality. Lymphoma / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Helicobacter Infections / epidemiology. Helicobacter pylori / pathogenicity. Humans. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944146.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Trubiani O, Recchioni R, Moroni F, Pizzicannella J, Caputi S, Di Primio R: Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res; 2005 Nov;39(4):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation.
  • Apoptosis is an important cell suicide programme involved in physiological and pathological processes.
  • Apoptosis can be induced in different ways depending on cell type and acquired signal.
  • Recently, it has been shown that, in addition to pineal gland, human lymphoid cells are an important physiological source of melatonin and that may be involved in the regulation of the immune system.
  • In this work, we examine the effect of melatonin on RAMOS-1 human leukaemic cells.
  • Cell growth and viability, DNA fragmentation and JC-1, and annexin V expression have been determined.
  • To elucidate the mechanism of action of melatonin, Western blot analyses for Bcl-2 and caspase-3 expression, and cytochrome c release were carried out.
  • The results suggest that the apoptotic effect of melatonin is associated with cell-cycle arrest, downregulation of Bcl-2, mitochondrial membrane depolarization, cytochrome c release and activation of caspase-3.
  • The intrinsic (mitochondrial dependent) pathway of caspase activation is the 'point of no return' commitment to cell death.
  • [MeSH-major] Apoptosis / drug effects. Burkitt Lymphoma / physiopathology. Melatonin / pharmacology. Mitochondria / physiology
  • [MeSH-minor] Annexin A5 / biosynthesis. Blotting, Western. Caspase 3. Caspases / metabolism. Cell Cycle / drug effects. Cytochromes c / biosynthesis. Down-Regulation. Enzyme Activation. Flow Cytometry. Humans. Membrane Potentials / drug effects. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16207299.001).
  • [ISSN] 0742-3098
  • [Journal-full-title] Journal of pineal research
  • [ISO-abbreviation] J. Pineal Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Proto-Oncogene Proteins c-bcl-2; 9007-43-6 / Cytochromes c; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; JL5DK93RCL / Melatonin
  •  go-up   go-down


91. Thornburg NJ, Kulwichit W, Edwards RH, Shair KH, Bendt KM, Raab-Traub N: LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene; 2006 Jan 12;25(2):288-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transgenic mice expressing Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) under the control of an immunoglobulin heavy-chain promoter and enhancer develop lymphoma at a threefold higher incidence than LMP1-negative mice.
  • Akt, JNK, and p38 were activated in LMP1-positive and -negative splenocytes as well as LMP1-positive and -negative lymphomas.
  • However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappaB c-Rel, was specifically activated.
  • Similarly to EBV-associated malignancies, p53 protein was detected at high levels in the transgenic lymphomas, although mutations were not detected in the p53 gene.
  • These data indicate that NF-kappaB is activated in LMP1-positive healthy splenocytes; however, NF-kappaB c-Rel is specifically activated in both the transgenic lymphomas and in the rare lymphomas that develop in negative mice.
  • The LMP1-mediated activation of NF-kappaB may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247482.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA019014; United States / NCI NIH HHS / CA / CA 19014
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Cytoskeletal Proteins; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM Domain Proteins; 0 / NF-kappa B; 0 / PDLIM7 protein, human; 0 / RELB protein, human; 0 / Receptors, Cell Surface; 0 / TNF Receptor-Associated Factor 1; 0 / TNF Receptor-Associated Factor 2; 0 / TNF Receptor-Associated Factor 3; 0 / Tumor Suppressor Protein p53; 0 / Viral Matrix Proteins; 147337-75-5 / Transcription Factor RelB; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


92. Rawal A, Finn WG, Schnitzer B, Valdez R: Site-specific morphologic differences in extranodal marginal zone B-cell lymphomas. Arch Pathol Lab Med; 2007 Nov;131(11):1673-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-specific morphologic differences in extranodal marginal zone B-cell lymphomas.
  • CONTEXT: Lymphoepithelial lesions (LELs) are a useful diagnostic feature of extranodal marginal zone B-cell lymphoma (EMZL); however, there is scant literature comparing their frequency and morphology at various sites.
  • OBJECTIVE: To evaluate any diagnostically useful, site-specific, morphologic patterns in EMZLs.
  • DESIGN: In this retrospective review, we evaluated 136 EMZLs from different sites for LEL pattern and other pathologic differences, including CD43 coexpression and plasma cell component features.
  • Monoclonal plasma cells were most common in breast, upper aerodigestive tract, skin, and salivary gland cases.
  • CONCLUSIONS: The relative importance of LEL pattern, CD43 coexpression, and clonal plasma cell component in EMZLs is site-dependent, and the differences may aid in the diagnosis of EMZLs at different anatomic sites.
  • [MeSH-major] Antigens, CD43 / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Diagnosis, Differential. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Male. Middle Aged. Retrospective Studies. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979485.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43
  •  go-up   go-down


93. Chbab N, Egerer A, Veiga I, Jarosinski KW, Osterrieder N: Viral control of vTR expression is critical for efficient formation and dissemination of lymphoma induced by Marek's disease virus (MDV). Vet Res; 2010 Sep-Oct;41(5):56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral control of vTR expression is critical for efficient formation and dissemination of lymphoma induced by Marek's disease virus (MDV).
  • Marek's disease virus (MDV) is an alphaherpesvirus that causes lethal T-cell lymphomas in chickens.
  • Comparative in vitro analysis of the viral and chicken TR promoters revealed that the vTR promoter (PvTR) was up to 3-fold more efficient than the chTR promoter (PchTR) in avian cells and that the stronger transcriptional activity of PvTR resulted largely from an E-box located two nucleotides downstream of the transcriptional start site of the vTR gene.
  • In vivo, growth of vPchTR+/+ was indistinguishable from that of parental virus; however, tumor induction was reduced by >50% and lymphomas were smaller and less disseminated when compared to those induced by parental virus.
  • We concluded that PvTR is not required for lytic replication in vivo but is essential for efficient transcription of vTR and thereby critical for efficient MDV lymphoma formation.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The authors, published by INRA/EDP Sciences, 2010.
  • [Cites] J Virol. 2000 Sep;74(17):7980-8 [10933706.001]
  • [Cites] J Virol. 2007 Oct;81(19):10575-87 [17634222.001]
  • [Cites] J Virol. 2000 Dec;74(23):11088-98 [11070004.001]
  • [Cites] Dev Growth Differ. 2000 Dec;42(6):613-21 [11142683.001]
  • [Cites] Curr Top Microbiol Immunol. 2001;255:25-55 [11217426.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1123-35 [11297687.001]
  • [Cites] Cell. 2001 Sep 21;106(6):661-73 [11572773.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):839-65 [11842096.001]
  • [Cites] J Virol. 2002 Mar;76(6):2952-63 [11861861.001]
  • [Cites] Virus Res. 2002 Jan 30;82(1-2):127-32 [11885939.001]
  • [Cites] Vet Microbiol. 2002 Apr 22;86(1-2):69-88 [11888691.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):257-65 [12398889.001]
  • [Cites] J Virol. 2003 May;77(10):5985-96 [12719590.001]
  • [Cites] J Virol. 2003 Dec;77(23):12841-51 [14610205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11815-20 [15289599.001]
  • [Cites] Virology. 2004 Oct 10;328(1):142-50 [15380365.001]
  • [Cites] Crit Rev Microbiol. 1986;12(4):293-320 [3007026.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] J Virol. 1991 Mar;65(3):1408-13 [1847460.001]
  • [Cites] Mutat Res. 1991 Jan;256(1):45-8 [1944386.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):4042-6 [1315048.001]
  • [Cites] Exp Gerontol. 1992 Jul-Aug;27(4):375-82 [1459213.001]
  • [Cites] J Virol. 1994 Dec;68(12):8239-53 [7966617.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] J Immunol. 1995 Oct 15;155(8):3711-5 [7561072.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1601-7 [7502069.001]
  • [Cites] Dev Genet. 1996;18(2):173-9 [8934879.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • [Cites] J Gen Virol. 1997 Sep;78 ( Pt 9):2191-8 [9292006.001]
  • [Cites] J Virol. 2004 Dec;78(23):13376-80 [15542691.001]
  • [Cites] J Virol. 2005 Jun;79(11):6984-96 [15890938.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23502-15 [15811851.001]
  • [Cites] J Virol. 2005 Sep;79(18):11647-59 [16140742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14831-6 [16203997.001]
  • [Cites] Biotechniques. 2006 Feb;40(2):191-7 [16526409.001]
  • [Cites] Nat Rev Microbiol. 2006 Apr;4(4):283-94 [16541136.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1307-17 [16651385.001]
  • [Cites] J Virol. 2007 May;81(9):4848-57 [17314164.001]
  • [Cites] Cytogenet Cell Genet. 2000;90(1-2):139-45 [11060464.001]
  • (PMID = 20423696.001).
  • [ISSN] 0928-4249
  • [Journal-full-title] Veterinary research
  • [ISO-abbreviation] Vet. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA127238; United States / NCI NIH HHS / CA / 5R01CA127238
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


94. Anandasabapathy N, Pulitzer M, Epstein W, Rosenman K, Latkowski JA: Pseudolymphoma evolving into diffuse large B-cell lymphoma. Dermatol Online J; 2008;14(5):22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudolymphoma evolving into diffuse large B-cell lymphoma.
  • Initial clinical and histopathologic features were consistent with a pseudolymphoma without gene rearrangements, and the patient was treated with intralesional glucocorticoids.
  • Four months later, the patient developed additional papules and plaques on the right arm, and, at this time, clinical and histopathologic features were most consistent with a T-cell-rich, large B-cell lymphoma, with monoclonal immunoglobulin light chain gene rearrangement.
  • The transformation of a pseudolymphoma into a large B-cell lymphoma is a rare event.
  • This patient's subtype, diffuse large B-cell lymphoma-other, carries an intermediate prognosis when compared to the more aggressive leg subtype and more indolent folliculocentric subtype.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Pseudolymphoma / pathology. Skin / pathology. Skin Diseases / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627758.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Hermann S, Rohrmann S, Linseisen J, Nieters A, Khan A, Gallo V, Overvad K, Tjønneland A, Raaschou-Nielsen O, Bergmann MM, Boeing H, Becker N, Kaaks R, Bueno-de-Mesquita HB, May AM, Vermeulen RC, Bingham S, Khaw KT, Key TJ, Travis RC, Trichopoulou A, Georgila C, Triantafylou D, Celentano E, Krogh V, Masala G, Tumino R, Agudo A, Altzibar JM, Ardanaz E, Martínez-García C, Suárez MV, Tormo MJ, Braaten T, Lund E, Manjer J, Zackrisson S, Hallmans G, Malmer B, Boffetta P, Brennan P, Slimani N, Vineis P, Riboli E: Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition. J Cancer Res Clin Oncol; 2010 Jan;136(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition.
  • INTRODUCTION: Lymphomas belong to the few cancer sites with increasing incidence over past decades, and only a few risk factors have been established.
  • We explored the association between education and the incidence of lymphoma in the prospective EPIC study.
  • MATERIALS AND METHODS: Within 3,567,410 person-years of follow-up, 1,319 lymphoma cases [1,253 non-Hodgkin lymphomas (NHL) and 66 Hodgkin lymphomas (HL)] were identified.
  • Cox proportional hazard regression was used to examine the association between highest educational level (primary school or less, technical/professional school, secondary school, university) and lymphoma risk.
  • RESULTS: Overall, no consistent associations between educational level and lymphoma risk were observed; however, associations were found for sub-groups of the cohort.
  • Concerning sub-classes of B-NHL, a positive association between education and risk of B cell chronic lymphatic leukaemia (BCLL) was observed only in women.
  • In both genders, the risk of diffuse large B cell lymphoma (DLBCL) was significantly lower for subjects with university degree (HR = 0.46, 95% CI = 0.27–0.79) versus lowest educational level.
  • [MeSH-major] Educational Status. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Diet. Europe / epidemiology. Female. Humans. Incidence. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Middle Aged. Prevalence. Proportional Hazards Models. Prospective Studies. Risk Assessment / statistics & numerical data. Risk Factors. Sex Factors. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2547-54 [7296505.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):813-20 [11714109.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] J Epidemiol Community Health. 2004 Oct;58(10):858-61 [15365113.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Am J Public Health. 2000 Aug;90(8):1277-81 [10937009.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):387-92 [6955544.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):554-9 [2703267.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):391-401 [17134891.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Int J Epidemiol. 1991 Jun;20(2):354-61 [1917234.001]
  • [Cites] Int J Cancer. 1991 Feb 1;47(3):352-7 [1993542.001]
  • [Cites] Int J Cancer. 1990 Mar 15;45(3):423-7 [2307531.001]
  • (PMID = 19582474.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Troxell ML, Bangs CD, Cherry AM, Natkunam Y, Kong CS: Cytologic diagnosis of Burkitt lymphoma. Cancer; 2005 Oct 25;105(5):310-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of Burkitt lymphoma.
  • BACKGROUND: The diagnosis and classification of lymphoma require correlation of morphologic, immunophenotypic, and molecular-cytogenetic studies.
  • Fine-needle aspiration biopsy (FNAB) is a valuable diagnostic technique that allows material to be collected for these ancillary studies, and for morphologic evaluation.
  • METHODS: The authors report a series of seven cases clinically or morphologically suspicious for Burkitt lymphoma.
  • However, only three of these cases represented Burkitt lymphoma, with one additional case of atypical Burkitt lymphoma.
  • The other cases included diffuse large B-cell lymphoma, monomorphic posttransplant B-cell lymphoma, and an aggressive B-cell lymphoma, with the latter case negative for c-myc rearrangement by FISH.
  • Of 2 non-Burkitt lymphoma specimens tested, 1 was positive for the immunoglobulin H/bcl-2 rearrangement, in addition to the c-myc rearrangement, suggesting transformation from a lower grade lymphoma.
  • CONCLUSIONS: These cases illustrated the value of FNAB in the diagnosis of Burkitt lymphoma, as well as the importance of obtaining material for, and integrating results of, ancillary studies for the final diagnosis.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Genes, myb / genetics
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Diagnosis, Differential. Female. Flow Cytometry. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Sensitivity and Specificity. Specimen Handling

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986398.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH: CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood; 2009 Oct 29;114(18):3864-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
  • A tumor-targeting antibody-IFN-alpha conjugate (mAb-IFN-alpha) could kill by direct actions of the monoclonal antibody (mAb) and IFN-alpha on tumor cells and also potentiate a tumor-directed immune response.
  • The 20-2b inhibits in vitro proliferation of lymphoma cells and depletes them from whole human blood more potently than the combination of veltuzumab and a nontargeting, irrelevant, mAb-IFN-alpha.
  • The 20-2b demonstrated superior therapeutic efficacy compared with veltuzumab or nontargeting mAb-IFN-alpha in 3 human lymphoma xenograft models, even though mouse immune cells respond poorly to human IFN-alpha2b.
  • These findings suggest that 20-2b merits clinical evaluation as a new candidate antilymphoma therapeutic.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2000 Jan;7(2):167-79 [10673721.001]
  • [Cites] J Exp Med. 2000 May 15;191(10):1777-88 [10811870.001]
  • [Cites] Immunity. 2001 Apr;14(4):461-70 [11336691.001]
  • [Cites] Cancer Immunol Immunother. 2002 Mar;51(1):15-24 [11845256.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1507-20 [11943735.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Nov;303(2):540-8 [12388634.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):214-21 [12612647.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):516-23 [12872134.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2868-78 [15102696.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6827-30 [15375003.001]
  • [Cites] C R Acad Sci Hebd Seances Acad Sci D. 1968 Nov 25;267(22):1900-2 [4973655.001]
  • [Cites] Nature. 1972 Sep 15;239(5368):167-8 [4561966.001]
  • [Cites] Ann Intern Med. 1980 Sep;93(3):399-406 [6159812.001]
  • [Cites] J Gen Virol. 1981 Nov;57(Pt 1):233-7 [6172550.001]
  • [Cites] Cancer Immunol Immunother. 1983;15(3):210-6 [6577942.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):597-601 [6692364.001]
  • [Cites] J Interferon Res. 1983;3(4):425-35 [6323591.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2507-12 [2411798.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5155-61 [2441862.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 [8108387.001]
  • [Cites] J Immunol. 1994 Nov 15;153(10):4604-15 [7963533.001]
  • [Cites] Immunol Today. 1996 Aug;17(8):369-72 [8783497.001]
  • [Cites] Blood. 1998 Apr 15;91(8):3017-27 [9531615.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(2):135-47 [9596485.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1947-53 [9712065.001]
  • [Cites] J Leukoc Biol. 1998 Sep;64(3):358-67 [9738663.001]
  • [Cites] Eur J Immunol. 1999 Mar;29(3):1041-50 [10092109.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1143-51 [10339671.001]
  • [Cites] Annu Rev Immunol. 1999;17:189-220 [10358757.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s [16203810.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):933-40 [16549598.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6 [16636283.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10):1678-88 [17015905.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2736-44 [16778139.001]
  • [Cites] Biochimie. 2007 Jun-Jul;89(6-7):884-93 [17532550.001]
  • [Cites] Mol Immunol. 2007 Sep;44(16):3823-37 [17768100.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5586s-5591s [17875793.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6881-8 [17982079.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):158-63 [18077530.001]
  • [Cites] Leuk Lymphoma. 2008 Jan;49(1):102-12 [18203019.001]
  • [Cites] Radiology. 2008 Feb;246(2):497-507 [18227543.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):613-26 [18687642.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8384-92 [18922911.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1062-70 [18941114.001]
  • (PMID = 19710501.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA103985; United States / NCI NIH HHS / CA / P01-CA103985
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 0 / veltuzumab; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC2773491
  •  go-up   go-down


98. Pedersen MØ, Hansen PB, Nielsen SL, Penkowa M: Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas. Leuk Lymphoma; 2010 Feb;51(2):314-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas.
  • Primary central nervous system lymphoma (PCNSL) in immunocompetent patients is highly malignant and has a poor prognosis.
  • The PCNSL molecular features are reminiscent to some degree of diffuse large B-cell lymphoma (DLBCL), yet PCNSL shows unique molecular profiles and a distinct clinical behavior.
  • This article characterizes the histopathology and expression profiles of metallothionein-I + II (MT-I + II) and their receptor megalin along with proliferation, oxidative stress, and apoptosis in PCNSL and in central nervous system (CNS) lymphomas due to relapse from DLBCL (collectively referred to as CNS lymphoma).
  • We show for the first time that MT-I + II and megalin are significantly altered in CNS lymphoma relative to controls (reactive lymph nodes and non-lymphoma brain tissue with neuropathology).
  • MT-I + II are secreted in the CNS and are found mainly in the lymphomatous cells, while their receptor megalin is increased in cerebral cells.
  • This morphology likely reflects the CNS lymphoma microenvironment and molecular interactions between lymphomatous and neuronal cells.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Low Density Lipoprotein Receptor-Related Protein-2 / analysis. Lymphoma, Large B-Cell, Diffuse / pathology. Metallothionein / analysis. Oxidative Stress
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Brain / drug effects. Brain / metabolism. Brain / pathology. Cell Cycle Proteins / analysis. Cell Proliferation / drug effects. DNA-Binding Proteins / analysis. Guanine / analogs & derivatives. Guanine / analysis. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Lymph Nodes / drug effects. Lymph Nodes / metabolism. Lymph Nodes / pathology. Malondialdehyde / analysis. Middle Aged. Minichromosome Maintenance Complex Component 7. Nuclear Proteins / analysis. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038220.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Low Density Lipoprotein Receptor-Related Protein-2; 0 / Nuclear Proteins; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 4Y8F71G49Q / Malondialdehyde; 5614-64-2 / 8-hydroxyguanine; 5Z93L87A1R / Guanine; 9038-94-2 / Metallothionein; EC 3.6.4.12 / MCM7 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7
  •  go-up   go-down


99. Kern JC, Kehrer JP: Free radicals and apoptosis: relationships with glutathione, thioredoxin, and the BCL family of proteins. Front Biosci; 2005;10:1727-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free radicals and apoptosis: relationships with glutathione, thioredoxin, and the BCL family of proteins.
  • Cellular fate is controlled by a number of factors within the cell, including an abundance of, and defenses against, free radicals generated both endogenously and exogenously.
  • Apoptosis is a preferred form of cell death because it is highly ordered resulting in the death of a cell with minimal effects on surrounding cells or tissues.
  • These antioxidant protective systems are not only involved in preventing stress, but also maintaining the normal functioning of specific transcription factors and the bcl proteins.
  • This review will discuss the association of reactive oxygen species with GSH, Trx and bcl proteins in apoptosis.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769662.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES013691; United States / NIEHS NIH HHS / ES / ES0715-25; United States / NCI NIH HHS / CA / R01CA83701; United States / NIEHS NIH HHS / ES / R01ES07784; United States / NIEHS NIH HHS / ES / R01ES09791
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Free Radicals; 0 / Transcription Factors; 136601-57-5 / Cyclin D1; 52500-60-4 / Thioredoxins; GAN16C9B8O / Glutathione
  • [Number-of-references] 161
  •  go-up   go-down


100. Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, Reed JC, Liddington RC: Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci; 2007 Jan;16(1):118-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein.
  • We report the crystal structure of N1L, which reveals an unexpected but striking resemblance to host apoptotic regulators of the B cell lymphoma-2 (Bcl-2) family.
  • Although N1L lacks detectable Bcl-2 homology (BH) motifs at the sequence level, we show that N1L binds with high affinity to the BH3 peptides of pro-apoptotic Bcl-2 family proteins in vitro, consistent with a role for N1L in modulating host antiviral defenses.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Apr;74(8):3815-31 [10729156.001]
  • [Cites] Cell. 1992 May 15;69(4):597-604 [1339309.001]
  • [Cites] J Gen Virol. 2002 Aug;83(Pt 8):1965-76 [12124460.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 Oct;58(Pt 10 Pt 2):1772-9 [12351820.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38676-82 [12167626.001]
  • [Cites] Annu Rev Immunol. 2003;21:377-423 [12543935.001]
  • [Cites] Mol Biol (Mosk). 2003 Jan-Feb;37(1):41-53 [12624944.001]
  • [Cites] Cell Death Differ. 2003 Jan;10 Suppl 1:S68-76 [12655348.001]
  • [Cites] J Virol. 2003 Jun;77(11):6093-100 [12743266.001]
  • [Cites] Immunity. 2003 Sep;19(3):341-52 [14499110.001]
  • [Cites] Cell Death Differ. 2003 Dec;10(12):1310-9 [12894216.001]
  • [Cites] J Virol. 2004 Jan;78(1):353-66 [14671117.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] J Cell Biochem. 2004 Apr 15;91(6):1099-108 [15048867.001]
  • [Cites] J Virol. 2004 Jul;78(13):7097-111 [15194786.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36570-8 [15215253.001]
  • [Cites] Nature. 1988 Sep 8;335(6186):176-8 [3412473.001]
  • [Cites] Virology. 1989 Aug;171(2):579-87 [2763467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3428-33 [11904405.001]
  • [Cites] J Mol Biol. 1993 Jan 5;229(1):105-24 [7678431.001]
  • [Cites] J Mol Biol. 1993 Sep 5;233(1):123-38 [8377180.001]
  • [Cites] Nature. 1993 Dec 23-30;366(6457):748-51 [8264798.001]
  • [Cites] Nature. 1994 May 26;369(6478):321-3 [8183370.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] Virology. 1998 May 10;244(2):365-96 [9601507.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21 [9757107.001]
  • [Cites] Protein Eng. 1998 Sep;11(9):739-47 [9796821.001]
  • [Cites] J Struct Biol. 1999 Apr-May;125(2-3):156-65 [10222271.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54470-8 [15471874.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4738-44 [15550399.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):15815-24 [15661737.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W193-7 [15980453.001]
  • [Cites] J Virol. 2005 Nov;79(22):14031-43 [16254338.001]
  • [Cites] Virology. 2006 Jan 5;344(1):139-50 [16364745.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:69-86 [16387678.001]
  • [Cites] J Virol. 2006 Feb;80(3):1140-51 [16414991.001]
  • [Cites] J Mol Biol. 2006 Feb 17;356(2):367-81 [16368107.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1651-62 [16439990.001]
  • [CommentIn] Protein Sci. 2007 Jan;16(1):2-3 [17192585.001]
  • (PMID = 17123957.001).
  • [ISSN] 0961-8368
  • [Journal-full-title] Protein science : a publication of the Protein Society
  • [ISO-abbreviation] Protein Sci.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI061139; United States / NIAID NIH HHS / AI / P01 AI055789; United States / NIGMS NIH HHS / GM / R01 GM060554; United States / NIAID NIH HHS / AI / AI055789; United States / NIGMS NIH HHS / GM / GM60554
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N1L protein, Vaccinia virus; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2222835
  •  go-up   go-down






Advertisement